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I. Abbreviations 
BSA     Bovine serum albumin 
CLSM     Confocal laser scanning microscopy 
CuAAC    Copper (I)-catalyzed alkyne-azide cycloaddition 
DEAE-dextran    Diethylaminoethyl-dextran 
DDS     Drug delivery system 
DLS     Dynamic light scattering 
EGF     Epidermal growth factor 
FDA     Food and drug administration 
FITC     Fluorescein isothiocyanate 
FT-IR     Fourier-transform infrared spectroscopy 
HPLC     High performance liquid chromatography 
IEF     Isoelectric focusing 
IgE     Immunoglobulin E 
IGF     Insulin-like growth factor 
MMP     Matrix metalloproteinase 
NGF     Nerve growth factor 
PEG     Poly (ethylene glycol) 
PGA     Poly (glycolic acid) 
PLA     Poly (lactic acid) 
PVA     Poly (vinyl alcohol) 
SDS PAGE    Sodium dodecyl sulfate poly (acrylamide) gel electrophoresis 
SEC     Size exclusion chromatography 
SEM     Scanning electron microscopy 
siRNA     Small interfering ribonucleic acid 
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SF     Silk Fibroin 
TGA     Thermogravimetric analysis 
USP     United States Pharmacopeia 
VEGF     Vascular endothelia growth factor 
WAX     Weak anion exchange chromatography 
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II. Abstract 
Around 100 years ago, Paul Ehrlich postulated the “magic bullet”, a personalized and tailored drug that 
can hit the affected tissue like a bullet from a gun. Since then on a lot of research has been conducted to 
develop such “magic bullets”. To deliver a drug to the target location, usually a carrier/vehicle is needed 
(drug delivery system). Conventional ways to administer drugs are by tablets or parenterals, whereas 
the latter often suffers from high plasma concentration for a short time period, followed by a more or 
less fast decrease of the plasma concentration. Depending on the elimination constant, repeated drug 
administration can lead either to a diminished effect if the active ingredient is fast eliminated, or to side 
effects if the active ingredient cumulates. To control the release, local drug release might be considered 
with the advantage that systematic side effects can be reduced. As a result, local drug delivery systems 
gain more and more interest with the challenge to achieve a sustained release without impacting the 
surrounding healthy tissue. In order to achieve this controlled drug delivery and an optimal therapeutic 
effect, a lot of research has been carried out for targeted delivery with a controlled release rate. However, 
a drug delivery system has to meet several requirements, e.g. mechanical stability, controllable structure 
and degradation. Due to its extraordinary properties (e.g. mechanical strength, biocompatibility, 
biodegradability into non-toxic products, FDA-approved), silk fibroin (SF) has been in the focus of 
research since a long time, especially in terms of sustained release drug delivery systems. One of the 
major advantages of SF compared to other biomaterials is that it can be assembled into a variety of 
matrices (e.g. particles, foams, gels, electrospun mats) [1, 2].  
The objective of the first study was to characterize silk fibroin in more detail. The focus was set on 
different purification processes of SF in order to efficiently remove sericin and a method to detect 
residual sericin was established. This is important to ensure biocompatibility since the combination of 
sericin and silk fibroin can cause allergic reactions. The degumming process significantly affected SF 
integrity, particularly mechanical strength and molecular weight distribution. These factors are crucial 
for the preparation of drug delivery systems, since they can influence the degradation rate of the drug 
delivery system and as a result, the release rate of the drug. 
The second study aimed to investigate the release behaviour of differently charged macromolecular 
drugs from SF films. Since biologicals and nucleic acids (respectively nucleic acid/polymer complexes) 
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are becoming an emerging field, the importance to understand the release behaviour of these 
macromolecular, charged compounds is growing. Therefore, differently charged, high molecular weight 
dextran derivatives, used as model drugs, were encapsulated into SF films and their release behaviour 
was studied. Additionally, the effect of SF purification process, with focus on degumming time, on drug 
release was elucidated. The release rate was found to be highly dependent on matrix properties, 
controllable via the purification process. 
In the third part, silk fibroin films were chemically modified via copper (I)-catalyzed alkyne-azide 
cycloaddition (CuAAC) to further control drug release. The already existing, extraordinary features of 
silk fibroin can be enlarged by chemical modification, extending their range of applications. By varying 
the modification degree, the release was controlled, aiming a more pronounced sustained release, and 
additionally, the surface properties with regard to hydrophilicity were tuned.  
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III. Zusammenfassung 
Vor rund 100 Jahren prägte Paul Ehrlich den Begriff "Zauberkugel", ein personalisiertes und 
maßgeschneidertes Medikament, das genau wie eine Kugel aus einer Waffe nur ein bestimmtes Gewebe 
trifft, ohne gesundes Gewebe zu beschädigen. Seit jeher bestrebt die Forschung, dieses Ziel zu erreichen. 
Um ein Medikament an den Zielort zu transportieren, wird üblicherweise ein Träger benötigt 
(Wirkstofffreisetzungssystem oder auch Drug Delivery System). Häufig vorkommende 
Darreichungsformen für Wirkstoffe sind, z.B. Tabletten oder Parenteralia, wobei Letztere den Nachteil 
besitzen, dass sie häufig die gesamte Wirkstoffmenge auf einmal freisetzen, was zu einer hohen 
Plasmakonzentration für eine kurze Zeitdauer führt. Je nach Eliminationskonstante kann es dann nach 
erneuter Wirkstoffapplikation zu einer mehr oder weniger schnellen Abnahme des Plasmaspiegels 
führen und somit auch zu einem Nachlassen der Wirkung, oder zu einer Wirkstoffakkumulierung und 
somit zu unerwünschten Nebenwirkungen. Um diesen Nachteil zu umgehen, kann die lokale 
Applikation in Betracht gezogen werden, so dass systemische Nebenwirkungen reduziert werde. Daher 
gewinnen Wirkstofffreisetzungssysteme, die lokal verabreicht werden können, immer mehr Interesse 
mit der Herausforderung eine gleichmäßig anhaltende Freisetzung zu erzielen, ohne dabei das 
umliegende, gesunde Gewebe zu beeinträchtigen. Um diese kontrollierte Arzneimittelabgabe und einen 
optimalen therapeutischen Effekt zu erreichen, wurde viel in diesem Bereich geforscht, so dass 
Wirkstoffe mit einer kontrollierten Freisetzungsrate an ihren Zielort im Körper transportiert werden. Ein 
Wirkstofffreisetzungssystem muss jedoch verschiedene Anforderungen erfüllen, z.B. eine hohe 
mechanische Stabilität, eine definierte Struktur und bekannte Abbauprodukte. Aufgrund der 
außergewöhnlichen Eigenschaften (z. B. mechanische Festigkeit, Biokompatibilität, biologische 
Abbaubarkeit zu ungiftigen Produkten, FDA-Zulassung), ist Seidenfibroin (SF) seit langem im Fokus 
der Forschung, insbesondere in Bezug auf Systeme mit verzögerter Wirkstoffabgabe. Einer der 
Hauptvorteile von SF im Vergleich zu anderen Biomaterialien besteht darin, dass es als Basis für eine 
Vielzahl unterschiedlicher Darreichungsformen verwendet werden kann (z. B. Partikel, Schäume, Gele, 
elektrogesponnene Fasermatten). 
Ziel der ersten Studie war es, das Seidenfibroin detaillierter zu charakterisieren. Der Fokus lag auf 
verschiedenen Aufreinigungsprozessen von Seidenfibroin, um das Sericin effizient zu entfernen und 
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eine Methode zum Nachweis von Rest-Sericin zu etablieren. Dies ist wichtig, um die Biokompatibilität 
sicherzustellen. Der Aufreinigungsprozess beeinflusste signifikant die SF-Integrität, insbesondere die 
mechanische Festigkeit und die Molekulargewichtsverteilung. Diese Faktoren müssen bei der 
Herstellung von Wirkstofffreisetzungssystemen bedacht werden, da sie Einfluss auf die Freisetzungsrate 
und auf den Abbau des Wirkstofffreisetzungssystems haben können. 
Die zweite Studie untersuchte das Freisetzungsverhalten von makromolekularen, unterschiedlich 
geladenen Modellwirkstoffen aus SF-Filmen. Da Biologika zu einem aufstrebenden Gebiet werden, 
wächst auch die Nachfrage, das Freisetzungsverhalten dieser Verbindungen besser voraussagen zu 
können. Daher wurden Dextran-Derivate mit hohem Molekulargewicht und unterschiedlicher Ladung 
aus SF-Filmen freigesetzt und die Freisetzungsraten untersucht. Zusätzlich wurde der Effekt des SF-
Aufreinigungsprozesses, vor allem hinsichtlich der Kochzeit der Seidenfibroin-Fasern, auf die 
Wirkstofffreisetzung untersucht. 
Im dritten Teil wurden SF-Filme über eine Kupfer (I) –katalysierte Huisgen-Cycloaddition (CuAAC) 
chemisch modifiziert, um eine verzögerte Freisetzung zu erreichen. Die bereits vorhandenen, 
außergewöhnlichen Eigenschaften von SF konnten durch chemische Modifikation ergänzt werden, 
wodurch auch der Anwendungsbereich erweitert werden. Die Freisetzung kann durch chemische 
Modifikation gesteuert werden und zusätzlich kann die Oberfläche maßgeschneidert werden, um somit 
die Wechselwirkung des Gewebes am Zielort und SF zu steuern. 
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1. Aim of the Work 
Naturally derived polymers can substitute inorganic and plastic materials. One of the major challenges 
is to identify a biopolymer that is capable to remain its chemo-physical properties as drug delivery 
system while fitting the current requirements of the technology and realizing a cost-competitive and 
convenient supply chain. Due to their mechanical stability along with other excellent properties (e.g. 
biocompatibility, biodegradability), silk materials are well suited for biomedical applications including 
drug delivery systems. Since chronic wounds are an emerging field due to the ageing population, the 
aim of this thesis was to produce a silk-based drug delivery system for topical applications. In general, 
the milieu of chronic wounds is characterized by overexpression of specific enzymes (matrix 
metalloproteinase MMP). The basic idea was to invent a drug delivery system with bioresponsive 
properties, meaning that a high amount of inflammatory enzymes in the wound can upregulate the 
release of anti-inflammatory drugs. As the characterization of the starting material is the critical step for 
the quality of the product, especially for naturally derived materials (due to the batch-to-batch 
variability), in a first study the silk material was characterized in detail. The main focus was set on an 
effective protein purification while retaining the silk fibroin (SF) integrity. Especially for early stage 
and scale-up production, it is essential to develop a robust and scalable SF purification and processing 
process, as well as the establishment of an analytical tool that allows material characterization. Besides 
various morphologies (particles, gels, foams, nonwovens, etc.), films are very interesting in terms of 
tissue engineering, for implant coatings and topical applications. Therefore, in a next step, SF films were 
loaded with model compounds in order to investigate release behaviour of drugs with different 
physicochemical properties (high molecular weight and different charges). In a last step, a way to 
chemically modify and thus, crosslink SF films was investigated and release behaviour of high 
molecular weight and differently charged model compounds was studied.  
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2. Theoretical Section 
2.1. Silk Fibroin as Biomaterial 
2.1.1.  Biomaterials 
The most accepted definition of biomaterial is currently defined by the American National Institute of 
Health, describing a biomaterial as “any substance or combination of substances, other than drugs, 
synthetic or natural in origin, which can be used for any period of time, which augments or replaces 
partially or totally any tissue, organ or function of the body, in order to maintain or improve the quality 
the quality of life of the individual” [3]. The range of use for biomaterials with synthetic and natural 
origin continues growing. Besides the traditional use of biomaterials for medical devices, implants and 
for tissue engineering, the application is widened to smart drug delivery systems and hybrid organs [4]. 
In general, biomaterials should be non-immunogenic and provide a broad range to control structure, 
morphology and function, while retaining their mechanical stability [5]. The major advantages of 
biomaterials are their biocompatibility and their biodegradability into non-toxic, water soluble products 
that can be excreted from the body [6]. Synthetic polymers, such as poly (glycolic acid) (PGA) and poly 
(lactic acid) (PLA), offer characteristics for sustained release up to several months, but they often need 
harsh conditions and organic solvents for their processing, limiting the biocompatibility [7]. Besides, 
the acidic degradation products restrict their use for protein therapeutics, since this may affect the 
product stability [8].  In contrast, natural polymers, such as collagen, albumin and elastin can be 
processed under mild conditions with the drawback that biopolymers tend to rapidly resolubilize in 
aqueous environment, since they are often hydrophilic, resulting in burst release profiles [9]. In addition, 
naturally derived materials are characterized by a wide batch-to-batch variety and concerns regarding 
sourcing. To meet these expectations, a natural-based product should provide enhanced product stability 
and tunable sustained release kinetics and as starting material, it should be well-characterized [7]. 
Silk as the “queen of all fabrics” was discovered around 2700 BCE in China and since then silk is a 
symbol of royalty and health [10]. Silk from mulberry silkworm Bombyx mori has been used for 
thousands of years to produce textiles due to its luster, softness, dyeability and light weight. In general, 
silk is produced by several worms of the order Lipedoptera (e.g. Bombycidae, Saturniidae) and by 
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members of Arachnida (more than 30 000 spider species) [11].  Among all these different silks, silk 
from the domesticated silkworm Bombyx mori and the spider silk of Nephila clavipes and Araneus 
diadematus are the most studied. In contrast to silkworms, spiders are able to produce seven different 
kinds of silk, e.g. for the nests, webs, egg protection, safety lines etc. [12]. In the fifth instar, the 
silkworm starts producing a large amount of silk in its inner pair of silk glands, within three days a 
cocoon is spun consisting of one fiber (300-1200m) [13]. After 15 to 20 days, the pupae hatches and 
emerges from the cocoon with a complete new physiology and morphology. 
Silk provides a unique combination of properties, beneficial for drug delivery (Table 1), including 
biocompatibility, biodegradation into non-toxic products [14], aqueous-based processing [15], and high 
mechanical strength [16]. On the basis of the background given above and the fact, that silk fibroin is 
already FDA approved, the following work focuses on silk derived from the domesticated silkworm 
Bombyx mori. 
Table 1. The unique combination of properties of silk for sustained drug delivery in distinction to synthetic polymer systems 
(e.g. PLGA), highlighted in bold. Reprinted  from [7] with permission from Elsevier. 
Structure 
Predominantly hydrophobic blocks, block copolymeric and modifiable 
sequence 
Self-assembly into β-sheet rich supramolecular structures 
Strong intra-/intermolecular physical interactions 
Stimuli-responsive crystal polymorphism 
High and tunable molecular weight 
Processing 
Aqueous-based ambient purification and processing capabilities 
Versatile material forms 
Suitability with common sterilization technologies 
Physicochemical 
properties 
Controllable network density, hydration resistance and swelling 
Controllable surface charge through sequence modifications 
High thermal stability 
Robust mechanical properties 
Tunable aqueous solubility 
Biological properties 
Low inflammatory/cytotoxic/immunogenic potential 
Enzymatic, surface mediated biodegradation 
Slow, controllable biodegradation rates 
Non-toxic, neutral biodegradation products (amino acids and peptides) 
Silk Fibroin as Biomaterial 
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Pharmacological properties 
Tunable release via diffusion- and biodegradation-controlled release 
Encapsulation of poorly soluble drugs 
Drug stabilization 
2.1.2. Structural Properties of Silk 
Silk comprises mainly two proteins, silk fibroin (SF) and sericin, whereas the latter forms a glue-like 
envelope around two fibroin brins (Figure 1). Sericin accounts for approximately 20 to 30% of the silk 
fiber, soluble in hot water due to the high content of hydrophilic amino acids (Table 2). Sericin is 
characterized by a broad molecular weight distribution (40-400 kDa) and reduces the shear stress during 
spinning [17].  
The SF itself consists of a heavy (approx. 350 kDa) and a light chain (approx. 25 kDa), connected via a 
disulfide bond at the C-terminus of the heavy chain and this disulfide bond might play a key role in β-
sheet formation [14].  
Additionally, a glycoprotein p25 (30 kDa) binds to the SF in a ratio of 6:1 (SF:p25) via hydrophobic 
interactions. The glycoprotein is important, on the one hand, for the maintenance of the structural 
integrity of the heavy and light chain complex, and on the other hand, for the formation of micellar 
structure, allowing the transportation of large fibroin amounts through the silk gland before spinning 
[18, 19].  
The amino acid composition of fibroin is primarily composed of approximately 45% glycine, 30% 
alanine and 12% serine, whereas tyrosine occurs at approximately 5% as one of the larger amino acid 
with a polar side chain (Table 2) [20]. 
Figure 1. The raw silk consists of two fibroin fibers glued together with a layer of sericin on their surfaces. Reprinted from 
[1] with permission from Elsevier. 
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Table 2. Amino acid composition of the polypeptides sericin and fibroin. Reprinted from [20] with permission from Elsevier. 
The light chain of SF is formed by 262 amino acids. As its size is much smaller compared to the heavy 
chain, the light chain plays a minor role in mechanical properties of SF. The heavy chain, as the major 
structural component of the protein, is characterized by amphiphilic, alternating block polymers, 
allowing the formation of β-sheets [20]. This co-polymer consists of 12 repetitive oligopeptide motifs 
GAGAGX (where X = alanine, serine or tyrosine), responsible for β-sheet formation, and 11 less 
repetitive, hydrophilic and bulky, amino acids, responsible for amorphous domains [2, 7]. These 
amorphous regions together with the hydrophilic C- and N-terminus (Figure 2a) give the molecule an 
overall negative charge (pI ~ 4) at physiological pH [19]. The crystalline regions form antiparallel β-
sheets in aqueous solution (silk II), where methyl side groups of alanine are pointing alternatively toward 
both sides of the β-sheet structure [21], allowing inter- and intramolecular intersheet stacking [22]. At 
air/water interface a helical structure is formed (silk III), involving an hexagonal packing of the SF 
molecules in a threefold helical conformation [23]. In contrast, the silk I structure is a water soluble 
Amino acid Sericin Fibroin 
Glycine 13.9 44.5 
Alanine 4.6 29.3 
Valine 3.2 2.2 
Leucine 1.2 0.5 
Isoleucine 0.7 0.7 
Serine 32.3 12.1 
Threonine 8.4 0.9 
Aspartic acid 14.5 1.3 
Glutamic acid 4.8 1.0 
Lysine 8.4 0.3 
Arginine 2.3 0.5 
Histidine 1.6 0.2 
Tyrosine 2.6 5.2 
Phenylalanine 0.4 0.6 
Proline 0.4 0.3 
Methionine 0.1 0.1 
Cysteine 0.3 0.2 
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form of SF (glandular state prior to crystallization) and is converted into the silk II structure upon 
exposure to heat or shear forces, or after methanol, ethanol or water vapor treatment [15, 24, 25]. The 
β-sheet structure is soluble in aqueous, chaotropic agents (lithium bromide, lithium thiocyanate, calcium 
chloride etc.), which are able to disrupt intermolecular hydrogen bonds between SF chains [26, 27]. 
After dilution, the solution is subsequently dialyzed in order to obtain an aqueous solution (see chapter 
2.1.3 Applications of Silk Fibroin) [24].  
However, the primary sequence of SF with its hydrophobic, repetitive and hydrophilic, non-repetitive 
domains allows the formation of micellar structures (Figure 2b), where the hydrophilic, terminal blocks 
define the outer structure of the micelle. The hydrophilic domains between the hydrophobic domains 
enable the micelles to remain soluble in water. Increasing SF concentration leads to increasing inter-
micellar interaction, resulting in the formation of globular structures and further in gelation (Figure 2c) 
[2]. 
These hierarchical structures, especially the ability of SF to form β-sheets, give the material its 
extraordinary strength and stiffness, exceeding the breaking strength and toughness of Kevlar and other 
Figure 2. a Heavy chain of Silk Fibroin with hydrophobic and hydrophilic blocks. b SF micelle. c SF globule, consisting of 
several micelles. d Fibrillar arrangement after application of physical shear. Reprinted from [2] with permission from 
Elsevier. 
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natural and synthetic polymers [28, 29]. In Table 3, the mechanical properties of silk and other fibrous 
materials are compared. 
Table 3. Comparison of mechanical properties of silk, and synthetic and natural fibers. Table adopted from [1] with permission 
from Elsevier. 
Material Young’s Modulus / GPa Ultimate Strength / % Breaking Strain / % 
Silkworm (Bombyx mori) 10-17 300-740 4-26 
β-sheet crystallites 
(Bombyx mori) 
22.6 - - 
Spider silk 10 1100 27 
Nylon 1.8-5 430-950 18 
Kevlar 130 3600 2.7 
The hydrogen bonds and Van der Waals interactions, present in the SF structure, contribute mainly the 
stability of this structure and result in strength and stiffness [30]. In contrast, the semi-amorphous matrix 
allows extensibility and toughness of the SF fiber. Upon tensile loading, the β-sheet structures orientate 
along the fiber axis (Figure 2d), whereas the semi-amorphous structures start to unravel [31].   
2.1.3. Applications of Silk Fibroin 
Textile industry. Silk fibroin with its unique properties provides a wide variety of application, not only 
as material for textiles but also as biomaterial in the medical and pharmaceutical field. Today, there are 
different natural (e.g. silk, wool) and synthetic (e.g. polyester) materials available for the textile industry. 
Due to its exceptional appearance and properties (soft texture, luster, dyeability and moisture-
absorbance ability), silk is still an attractive textile choice, especially for luxurious clothing. To achieve 
the softness and luster of the silk fabrics, the sericin has to be removed by a so-called degumming 
process (degumming, since the sericin constitutes the glue between the two fibroin filaments). During 
unreeling of the cocoons and followed by knitting or weaving into fabrics, the sericin remains on the 
fiber in order to protect it. In contrast to fibroin, sericin is soluble in hot water due to high amount of 
hydrophilic amino acids (Table 2). After the production of the silk textile, the degumming is 
traditionally carried out in Marseille soap and elevated temperature (90-95°C). However, this treatment 
takes up to six hours and might affect SF fibers [32].  
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SF purification. For an effective sericin removal for biomedical applications, the purification of SF is 
commonly carried out using a 0.2 M sodium carbonate solution at 100°C for at least one hour (Figure 
3a). After drying, the SF fibers are dissolved in a highly concentrated salt solution (e.g. 9 M lithium 
bromide) and in a next step, the salt is removed via dialysis (Figure 3a). Further treatments for an 
effective removal of sericin are discussed in 3.1 Effects of Degumming Process on Physicochemical and 
Mechanical Properties of Silk Fibroin. The sericin removal is not only for optical but also for health 
purposes, since the combination of both silk proteins, fibroin and sericin, can lead to allergies (see 
following paragraph).  
Bio-response to silk. Biological responses to silk have been reported mainly related to allergic reactions, 
especially type I allergic responses and elevated immunoglobulin E (IgE) level, when patients had 
contact with silk sutures [33, 34]. Additionally, respiratory response, e.g. asthma, was manifested after 
silk contact and sericin was accused to trigger T-cell mediated allergic response [35, 36]. Nevertheless, 
sericin features several biological properties, e.g. anti-oxidant, anti-inflammatory, collagen promoting 
and tumor inhibitory effects, and, thus, has been investigated for its use in medical applications [37]. 
Due to the weak structural properties and the high water solubility, sericin is more applicable in the field 
of neural applications. Unfortunately, the simultaneous presence of both proteins, silk fibroin and 
sericin, decrease the biocompatibility and limit the application of the virgin silk. Hence, the sericin has 
to be removed by the above-mentioned degumming process. However, further investigations regarding 
the immune response and extensive characterization of macrophage invasion and locally released 
cytokines is needed to pioneer the application of SF based drug delivery systems [38]. 
Suture material. Low bacterial adherence and the high mechanical strength enable the use of SF as suture 
material since centuries. As defined by the US Pharmacopeia (USP), silk fibroin (suture) material is 
absorbable (“loses most of its tensile strength within 60 days”) and non-degradable [1]. Nonetheless, SF 
was shown to be degradable in recent studies but over a longer period, e.g. SF suture material loses the 
majority of its tensile strength within one year [5, 39], depending strongly on the purification process of 
fibroin (short vs. long degumming), the kind of system (porous vs. dense) and the implantation site. Due 
to the fact, that silk fibroin is used as a suture material for surgeries, it is already FDA approved, making 
it an attractive basis for drug delivery systems, tissue engineering and other medical devices. One fibroin 
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based scaffold, which passed the regulatory scrutiny, is the Seri® Surgical Scaffold (Allergan, MA, 
USA), which is functionalized with RGD motifs to promote cellular growth. This scaffold is used for 
soft tissue repair and crucial ligament repair [40], paving the way for further application of SF-based 
drug delivery systems. 
A lot of research has been conducted for SF based drug delivery systems, since SF can be assembled in 
a variety of matrices, e.g. particles, hydrogels sponges, fibers and meshes (Figure 3a), delivering a wide 
range of active molecules, such as genes, small molecules and biologicals. The purified silk fibroin 
solution can be processed into a variety of morphologies with attractive features, e.g. large surface area 
and high porosity [41].  
Figure 3. Purification of Silk Fibroin, a. made from silkworm cocoons and b. solubilized fibers, which are left intact (to keep 
the stability) until the final processing. Reprinted with permission of Elsevier [38]. 
Hydrogels. Silk fibroin hydrogels are characterized by their ability to swell in water without dissolution, 
imitating the physical and mechanical properties of tissue (skin, cartilage). The gelation of SF is 
controllable via pH, temperature and calcium ion concentration, and in addition via protein 
concentration, where increasing protein concentration leads to faster gelation. Besides, the pore size of 
the hydrogel can be impacted by the protein concentration [42]. Especially for minimally invasive 
surgeries, injectable hydrogels are attractive scaffolds as well as for the delivery of cells and cytokines. 
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Sponges. SF sponges with a high porosity (up to 97%) can be prepared by lyophilization, porogens and 
gas foaming, and by leaching of solvents (e.g. hexafluoro-2-propanol) [43]. Sponges provide a high 
interior surface area with interconnected spaces and a defined three-dimensional volume, allowing the 
invasion of cells, their attachment and growth. In addition, nutrients and oxygen can easily diffuse into 
the sponges [28, 44]. These properties together with the possibility to produce different pore sizes make 
them an attractive scaffold for tissue engineering. 
Mats. Electrospinning is a favourable process to produce SF fiber mats with a wide range of fiber 
diameter (nanometer to a few micrometers), depending on the mode of processing and resulting in high 
surface area [45]. Briefly, for the production of SF fibers a strong electrical field is applied between the 
polymer solution and a collector plate [46, 47]. As mentioned before, the high surface area is important 
for cell attachment and enables the imitation of extracellular matrix of natural tissue.  
Particles. SF particles can range from high nanometer up to several micrometers with a spherical shape, 
allowing a wide variety of applications for controlled drug delivery. The ability of SF to self-assemble 
can be utilized to form microspheres, e.g. by salting out with potassium phosphate [48]. The particle 
size can be varied by the type of salt and the ionic strength, leading to displacement of protein-water 
interaction and the ease of hydrophobic protein-protein interactions. A second method to produce 
particles is a technique so-called prilling or laminar jet break-up method. In brief, the aqueous SF 
solution is pumped with a syringe pump through a vibrating nozzle, so that the jet turns into droplets. In 
order to avoid agglomeration of the particles, a high voltage is applied and as a result, the droplets are 
repulsing each other. The droplets are falling into a hardening bath to induce water insolubility (e.g. 
with methanol) or are immediately frozen with liquid nitrogen [49]. The size of the prilled particles is 
dependent on the nozzle size and ranges between 100 and 400 µm. An additional method for particle 
production is the use of lipid vesicles as templates or by blending with poly (vinyl alcohol) (PVA) [48, 
50]. 
Films. SF films can be casted from aqueous and organic solvent systems, aiming a straightforward 
biomaterial with a less complex nature compared to the systems mentioned before. Depending on the 
content of silk I or II, SF films are water vapour and oxygen permeable [51]. Furthermore, the diffusity 
through the film and the degradation rate can be controlled via the purification process (see also 3.2 Silk 
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Fibroin Degumming affects Scaffold Structure and Release of Macromolecular Drugs). Particularly for 
controlled drug delivery, the release kinetics are a key factor to control the drug level in the body within 
the therapeutic window. SF films offer a number of advantages due to the ease of production and the 
consistency of the material. In addition, proteins and enzymes are stabilized within the SF matrix, 
allowing the release of fully active proteins and enzymes [8]. 
In general, all the above-mentioned matrices can be loaded with an active pharmaceutical ingredient, 
ranging from small molecules to high molecular weight biologicals. Table 4 provides an overview of a 
small section of the research already carried out [7]. The encapsulation can be achieved by simple mixing 
of the SF solution with the compound and subsequently, further processing. 
Table 4. Silk-based formulations of small molecule and biological drugs with their sustained release data in vitro. VEGF = 
vascular endothelial growth factor, EGF = epidermal growth factor, NGF = nerve growth factor, IGF = insulin-like growth 
factor, BSA = bovine serum albumin. Table adopted from [7] with permission from Elsevier. 
Formulation Drug 
Sustained release duration / 
days 
Hydrogels 
Penicillin 2-4 
Dexamethasone 2 
Inulin 45 
VEGF 42 
Electrospun 
fibers/mats/tubes/scaffolds 
EGF 7 
NGF 28 
Particles 
Salicylic acid 1 
Propranolol HCl 28 
Insulin << 1 
IGF-1 14-49 
Films 
Clopidogrel 28 
Gentamicin 5 
BSA 28 
EGF 22 
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2.2. Matrix Metalloproteinase Triggered Bioresponsive Drug Delivery Systems – 
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Abstract 
Engineering of drug delivery systems has evolved in recent decades from comparably simple designs 
that merely controlled drug release to complex, often multistage systems that respond to multiple 
biological or environmental stimuli. Matrix metalloproteases (MMPs) are a family of proteolytic 
enzymes that are involved in numerous physiologic and pathophysiologic processes, including cancer. 
Therefore, these enzymes represent highly relevant targets for the development of novel bioresponsive 
drug delivery systems. The first part of this review summarizes major developments of the various types 
of MMP responsive drug delivery systems that have been achieved in the last decade and highlights 
promising strategies. The selection and incorporation of MMP sensitive elements into drug delivery 
systems as well as the interaction between MMP, drug delivery system and drug require additional 
scrutiny to avoid common pitfalls. Thus, the second part of this review focusses on strategies for 
successful selection and incorporation of MMP sensitive elements and on important design parameters 
related to the drug delivery system and the drug. This review will therefore provide a broad overview 
of successful MMP-sensitive drug delivery system designs and will inform about important design 
criteria for novel systems. 
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1. Introduction 
Paul Ehrlich’s vision of the “magic bullet” that targets a defined cellular structure, resulting in specific 
and efficient attack of pathogens or diseased tissue while leaving healthy tissue unaffected does not fail 
to inspire scientists even today [52]. Since Ehrlich’s days however, the knowledge on the origin and 
progression of diseases, most notably various forms of cancer, has evolved significantly. Despite still 
being the most important strategy, chemical targeting of the drug molecule alone frequently is 
insufficient to obtain a true “magic bullet”. Drug delivery systems (DDS) can introduce additional 
targeting functionalities, which are virtually independent from the chemical characteristics of the 
therapeutic drug molecule. This includes diverse strategies such as localized drug delivery, systemic 
targeting (e.g. by ligand-receptor mediated targeting and locally activated delivery systems) and 
intracellular targeting [53, 54]. Among those strategies, locally activated delivery systems appear 
interesting due to their broad applicability in systemic targeting and localized delivery alike, and the 
high specificity achievable with this strategy. Local activation may be achieved by changes of the pH 
value, through reduction or oxidation or by enzymatic degradation or numerous other principles. Within 
this review, targeting strategies based on enzymatic activation using matrix metalloproteinases (MMP) 
will be discussed. 
MMPs are a family of zinc-dependent endopeptidases with at least 24 different types which play a 
central role in numerous physiological and pathological processes [55]. The different MMP types are 
frequently categorized into four main classes according to their substrate specificity and their cellular 
localization: collagenases (MMP-1, MMP-8 and MMP-13), gelatinases (MMP-2 and MMP-9), 
stromelysins (MMP-3, MMP-10, MMP-12) and membrane-type MMPs (MT1-MMP, MT2-MMP, 
MT3-MMP, MT4-MMP) [56]. While MMPs were initially recognized for their role in extracellular 
matrix (ECM) degradation in the context of cancer cell invasion and metastasis, this simplistic view was 
later revised and the importance of MMPs in regulating the entire extracellular signaling milieu was 
identified [57, 58]. MMPs consequently are involved in numerous physiological processes such as cell 
proliferation, differentiation, adhesion, migration, survival, and in cell-cell interactions. 
In the context of MMP activity it is important to note that proteases do not simply act in a linear fashion, 
but their actions are concerted within the so called “protease web” consisting of MMPs and MMP 
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inhibitors, their substrates and other proteases and resulting in tissue homeostasis. Homeostatic balance, 
however, might be disturbed by inhibition of a whole class of proteases or of a single member of the 
network. Subsequently, other proteases can either compensate for lost activity or even inhibition of a 
single protease may unleash a cascade of events that results in deleterious consequences for the tissue 
or the entire body [59]. As a result, great care must be exercised and the entire interplay between the 
target MMP and other members of the protease web must be understood not only in the case of broad 
spectrum MMP inhibition but also with highly selective MMP inhibitors.  
Alternatively, MMP overexpression may be employed as a trigger for drug delivery systems, leading to 
localized, on-demand drug release without the necessity of direct MMP inhibition. Because of 
accumulation of MMPs in the extracellular space and significance of MMP overexpression in various 
diseases, MMPs are excellent target molecules for triggered drug release.  
The design and application of such MMP-activated systems may be approached from different angles 
and the complexity of the delivery systems ranges from comparably simple, low molecular weight 
molecules to sophisticated multi-stage drug delivery systems. The concept of protease-activated 
prodrugs (PAP) that are activated specifically by proteases overexpressed in tumor tissue was 
established already in 1980 and has been applied in various iterations since then [60]. The original 
concept of PAP was based on peptidyl prodrugs where an anticancer agent was coupled to a protease 
sensitive peptide. However, it was found that differences in protease expression between tumor and 
normal tissues alone might not result in sufficient tumor specificity and that short drug half-life in 
circulation limited efficient distribution to the target site. The blood half-life and preferential 
accumulation of PAP therapies at the target site was further improved through conjugation of 
macromolecular compounds such as albumin, N-(2-hydroxypropyl) methacrylamide copolymer or 
dextran [61]. More recently, even larger and more complex delivery systems such as various protease-
sensitive nanoparticles and hydrogels were developed. As an example, MMP-sensitive multi-stage 
nanoparticles are capable of efficient extravasation into the tumor, followed by MMP triggered 
disassembly and size reduction, improving diffusion in the interstitial space of the tumor [62]. 
In their review published in 2007, Vartak and Gemeinhart provided an insightful summary on the 
development of MMP-activated drugs [55]. After more than 10 years of research in the field, we herein 
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review the current state of MMP activated drug delivery systems from prodrugs to complex protein and 
nucleic acid delivery systems. Furthermore, design considerations and general challenges associated 
with MMP-activated drug delivery systems will be discussed in detail to guide readers to successful 
implementation of MMP activation. Finally, we will address issues around synthesis of MMP 
activatable elements and discuss their successful incorporation into DDS.  
2. Drug delivery systems utilizing MMP responsive elements 
Enzymes such as MMP exhibit high efficiency on substrates and are frequently overexpressed in specific 
tissues and/or specific disease states [63]. These characteristics can be exploited for the design of 
“smart” linkers between the drug and a carrier, which are designed to be stable during storage, 
administration, in the blood circulation or under physiologic conditions but are enzymatically cleaved 
upon contact with specific MMPs. This ideally leads to increased local concentrations at the site of 
disease. Such “smart” systems can be applied in various ways in the design of drug delivery systems. 
The recent progress in the development of bioresponsive, MMP-activated systems will be described in 
the following sections with regards to different categories of drug delivery systems. 
2.1. Carrier-peptide-drug conjugates 
Targeting of systemically administered low molecular weight drugs e.g. to tumor tissue is complicated 
by drug instability in the circulation, rapid clearance and distribution to non-target tissues.  
Overexpression of several members of the MMP family is characteristic for numerous tumors. Hence, 
protease activated prodrugs (PAP), where a MMP cleavable peptide substrate was linked to a drug 
molecule, were developed to trigger release and activation of the drug only at the tumor site [64]. Since 
PAPs frequently suffered from non-specific activation and fast clearance, the basic concept was 
expanded to include macromolecular carrier molecules to allow a longer circulation time, improved 
tissue accumulation, protection from degradation and premature drug release [65]. This type of 
bioresponsive, long-circulating delivery system was first introduced by Kratz et al. and Mansour et al. 
by combining PAP incorporating doxorubicin (DOX) with albumin as macromolecular carrier, either 
by synthesis of albumin-PAP conjugates or by rapid binding of an activated PAP to circulating albumin 
[66, 67].  
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In recent years, the concept of carrier modified PAP has evolved further. On the one hand, synthetic 
polymers were introduced as macromolecular carriers, on the other hand, additional functionalities have 
been added to the delivery systems. Various synthetic carrier molecules were studied instead of natural 
carriers such as albumin, allowing for synthesis of well-defined products at high purity and simplifying 
further modification, e.g. for tailored solubility, improved pharmacokinetics or intracellular delivery of 
the cargo [68, 69].  
As an example, PAPs have been modified with cell penetrating peptides (CPP) to induce cellular uptake 
at the target site [70-73]. In these delivery systems, CPP activity is reduced or entirely inhibited as long 
as the conjugate is intact. After cleavage of MMP-specific peptide linkers at the target site, CPP are 
released and facilitate cellular uptake of cytotoxic drugs (e.g. DOX or protoporphyrin). 
Building on this concept, multistage drug delivery systems, combining MMP-cleavable elements with 
CPPs and active targeting moieties were developed. Chen et al. set out to deliver trichosanthin (TCS), a 
ribosome-inactivating protein with reported high antitumor activity, to malignant glioma [74]. To 
achieve this goal the macromolecular drug delivery system must overcome the blood-brain-barrier 
(BBB) as well as the cell membrane of glioma cells. Furthermore, unspecific toxicity from TCS must 
be curtailed. The authors therefore combined TCS with lactoferrin (LF), assisting with penetration of 
the BBB and targeting. An MMP-2 sensitive peptide was used to conjugate LF to TCS/CPP. Upon 
reaching its target, elevated MMP-2 levels at the tumor site induce the release of TCS/CPP portion of 
the DDS and CPP facilitates the delivery of TCS into the cytoplasm of glioma cells (Figure 1). 
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Figure 1. (A) Multistage DDS combining cytotoxic drug (TCS toxin) with CPP and lactoferrin. (B) Lactoferrin facilitates 
targeting and penetration of the BBB through binding to low-density lipoprotein receptor-related protein 1 (LRP-1). (C) 
Elevated MMP-2 levels at the tumor site result in separation of TCS/CPP portion from lactoferrin and CPP mediates TCS 
delivery to the cytosol of glioma cells. Reproduced under the terms of CC BY-NC from [74]. 
Besides cytotoxic drugs, also cytolytic peptides are candidate drugs for smart, MMP-activated delivery 
system. Cytolytic peptides can oligomerize on the cell surfaces, resulting in transient pore formation 
and cell lysis. However, very similar to highly potent cytotoxic drugs, the therapeutic application of 
these natural weapons, e.g. wasp venom, is complicated by cytotoxicity resulting from non-specific lytic 
activity and rapid elimination after injection [75]. The major challenges associated with application of 
cytolytic peptides have been tackled by conjugation to polymeric carriers (e.g. poly (L-glutamic acid), 
PGA) via MMP-sensitive linker peptides. On the one hand, conjugation to the carrier molecule renders 
cytolytic peptides inactive, on the other hand, circulation half-life of the conjugate is increased. Specific 
cleavage of the MMP sensitive linker at the tumor site releases the cytolytic peptide and reestablishes 
cytolytic activity. After three hours of in vitro incubation with target cells a significant amount of the 
modified peptide-mitoparan-PGA conjugate had been endocyted and mitoparan was released after 
proteolytic cleavage [75]. The authors concluded that overall loading of the conjugate could represent a 
challenge from a pharmacological point of view. Nevertheless, active and passive targeting as well as 
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spatially controlled activation could result in sufficiently high local concentrations at the tumor site and 
appropriate pharmacological effects.  
These considerations represent critical issues, which may be valid for the majority of carrier-peptide-
drug conjugates described in this chapter. These delivery systems are generally chemically well-defined 
and simply constructed and hence, response to their environment can be tightly controlled. On the other 
hand, drug load is often and possibly inherently low, therefore requiring highly efficient targeting as 
well as spatiotemporal activation to result in sufficient efficacy. Furthermore, and in conjunction with 
the previous point, these systems critically depend on highly efficient drug molecules, which exert their 
effect already at very low concentration. This, on the other hand, frequently results in severe systemic 
or unspecific toxicity, which must be tackled by the delivery system. Finally, efficiency frequently 
depends on intracellular delivery of the cargo, which often requires incorporation of CPP.  
2.2. MMP-responsive, particulate drug delivery systems 
Similar bioresponsive elements as described above (Section 2.1.) have also been introduced into 
particulate drug delivery systems, e.g. micelles, complexes or nanoparticles. These delivery systems 
allow drug encapsulation as well as chemical coupling of the drug to its building blocks or both, resulting 
in higher drug load compared to carrier-peptide-drug conjugates. Like carrier-peptide-drug conjugates, 
these delivery systems are primarily employed to improve circulation half-life and solubility of the drug, 
reduce off-target toxicity and to achieve targeting to specific tissues and/or to improve cellular uptake. 
As with carrier-peptide-drug conjugates, different MMP responsive drug delivery systems of different 
complexity have been developed. In the following chapters, the recent progress is reviewed, focusing 
on the most common systems, i.e. self-assembled systems and solid nanoparticles. 
2.2.1. MMP responsive, self-assembled drug delivery systems   
The majority of self-assembled MMP-responsive drug delivery systems represent micelles, liposomes 
or polymersomes, which are all based on amphiphilic building blocks. Micelles are spontaneous self-
assemblies with a core-shell structures consisting of a hydrophobic core, frequently used for drug 
loading, and a hydrophilic shell. Liposomes, on the other hand, are self-assembled from lipids, forming 
bilayer or multilayer structures and allowing encapsulation of both hydrophobic and hydrophilic drugs. 
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Finally, polymersomes typically consist of diblock- or triblock copolymers, forming liposome-like 
structures but are characterized by higher stability and increased ease of chemical modification.  
One of the main disadvantages of peptide-drug conjugates, i.e. short circulation half-life, led Lee et al. 
to synthesize MMP-2 sensitive PEG-peptide-DOX conjugates, which spontaneously formed micelles 
[76]. The efficacy of these micelles was further enhanced by loading with free DOX. Like peptide-drug 
conjugates, micelles disassembled in the presence of MMP-2, triggering release of the drug. High 
loading efficiency of > 98 % and drug load of > 60 wt% was achieved due to hydrophobic interactions 
between the loaded and conjugated DOX. The unloaded and DOX loaded micelles showed lower 
cytotoxicity and improved half-lives (t1/2 = 11.4 – 15.2 min) compared to free DOX (t1/2 = 1.6 min). 
Similar delivery systems were developed based on PEGylated lipids in conjunction with MMP-9 
cleavable lipopeptide, which also disassembled in the presence of elevated MMP levels [77]. In this 
case, drug release was triggered by two consecutive steps: firstly, the PEG shell was shed in the presence 
of elevated glutathione concentrations, followed by degradation of MMP-sensitive peptide leading to 
disassembly and drug release. The authors confirmed efficiency of the delivery system in vitro, showing 
that MMP-9 was required for efficient uptake and drug release in a cell spheroid model. In addition, 
efficient and localized drug release was observed in the tumor microenvironment and in vivo tumor 
growth was better controlled with MMP-9 sensitive vesicles compared to vesicles without MMP 
substrate. Protease and reduction-triggered drug release in the tumor microenvironment was also 
investigated by Xu et al. through combination of MMP-sensitive, drug containing micelles which were 
incorporated into reduction-sensitive liposomes [78] and by Hou et al. through self-assembly of a 
conjugate consisting of a photosensitizer (chlorin e6), a MMP-2 sensitive peptide and reduction sensitive 
PEG [79].  
Complex, multistage systems offer the possibility to combine multiple drug delivery- and targeting 
strategies and hence improve specificity and reduce side effects. As an example, Zhu et al. developed 
micelles composed of a PEG-MMP-2-sensitive peptide-paclitaxel conjugate as drug carrier, a TATp-
PEG-phosphoethanolamine (PE) conjugate to facilitate cell internalization and PEG-PE as micelle 
building block [80]. Significant accumulation of the rhodamine-labeled micelles was found in the liver 
and the tumor of non-small cell lung cancer xenograft mice due to substantial expression of MMP-2 in 
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these tissues. The high local concentration might be explicable by cell internalization, whereas tumor 
accumulation was contingent on enhanced penetration and retention (EPR) effect and high MMP-2 
expression. When non-sensitive micelles and MMP-2 sensitive micelles were administered, no 
significant difference of paclitaxel (PTX) accumulation was found in the major organs and blood, while 
tumor accumulation was 2.5 times higher for MMP-2 sensitive micelles. A similar strategy was applied 
for a liposomal system by the same group [81]. Two functional PEG-lipid conjugates, TATp-PEG-lipid 
and mAb-PEG-MMP2 cleavable peptide-lipid were synthesized and used to prepare liposomes.  In this 
case, besides de-shielding of TATp, the liposome also contained a cancer-specific mAb enabling active 
targeting to tumor cells and subsequent receptor-mediated endocytosis. The authors, however, 
concluded that from a practical point of view the combination of active targeting and MMP2-sensitive 
de-shielding of TATp may not be required since the EPR effect in combination with MMP-triggered 
TATp de-shielding could result in sufficient delivery efficiency to tumor cells. Yet again a very similar 
approach was chosen by Gao et al., who used tumor microenvironment-sensitive polypetides (TMSP) 
which consisted of polycationic CPP and polyanionic shielding peptide, connected by a MMP-sensitive 
linker [82]. Docetaxel loaded lipid carriers were prepared using TMSP-PEG-lipid and folate-PEG-lipid 
conjugates and were tested in vitro in cell culture and cell spheroids as well as in vivo in tumor bearing 
mice. Interestingly, in this study MMP-triggered de-shielding of CPP and active targeting to folate 
receptors appeared to show additive effects, suggesting that the combination of these two delivery 
modalities could further increase efficacy and specificity of drug delivery systems.  
MMP-specific PEG disassembly or de-shielding is a strategy quite frequently employed for self-
assembled drug delivery systems by several research groups, either alone or in combination with cell 
penetration enhancers, RGD motifs or other targeting moieties [83-88].  
In addition to size reduction through PEG disassembly, alternative morphological transitions such as 
aggregation and network formation may be triggered by MMP activity. This approach has been 
proposed by Chien et al. and Nguyen et al., who used amphiphilic block copolymers for micelle 
formation which were modified with brush like, hydrophilic and MMP-degradable peptides (Figure 2 
A and B) [89, 90]. Micelles were able to freely circulate until extravasation at a site with elevated MMP 
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expression. Upon contact with MMP, micelles were transformed into network-like scaffolds (Figure 2 
C-F) which were retained in the tissue up to 28 days post injection. 
Figure 2. (A) Structure of brush peptide-polymer amphiphile with MMP-sensitive peptide sequence (underlined). Upon dialysis 
into aqueous buffer, these amphiphilic polymers self-assemble into nanoparticles. (B) Schematic  of nanoparticles circulating 
in the bloodstream, followed by extravasation through leaky vasculature at myocardial infarction site and formation of 
aggregate-like network due to MMP activity. (C-E) MMP responsive nanoparticles (top) show morphological transition in the 
presence of MMP (C vs. D and E) while nonresponsive control nanoparticles (bottom) morphology is unaffected. (F) 
Hydrodynamic diameters of MMP responsive (top) and nonresponsive (bottom) nanoparticles prior to and after MMP addition. 
Reprinted from [91] with permission from Wiley. 
Finally, active targeted delivery of lipid micelles to MMPs was published by Ngyuen et al. for therapy 
of coronary heart disease [92]. After myocardial infarction drug delivery is limited by low permeability 
of vasculature and short-time upregulation of specific cardiac markers [93]. Since MMPs play a key 
role in remodeling and restructuring after myocardial infarction [94], a novel micelle was developed 
containing an MMP targeting peptide (MMP-TP micelles), which facilitated specific accumulation due 
to myocardium-specific MMP upregulation [92]. One day after systemic injection no significant 
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superiority of the MMP-TP micelles over non-targeted micelles was found, but at day 3 and 7, 
accumulation of MMP-TP micelles exceeded non-targeted micelles by a factor of 2 to 3. The micelles 
showed the ability to efficiently accumulate in the infarcted area of the heart while leaving healthy tissue 
unaffected. Similarly, Fab fragments against MT1-MMP have been used to actively target DOX loaded 
liposomes in vitro and in vivo [95, 96]. This approach represents a very interesting alternative strategy 
to classic MMP-responsive drug delivery utilizing specific overexpression of MMPs in certain disease 
states.  
2.2.2. MMP-responsive micro- and nanoparticles 
MMP-responsive elements have been widely used not only in self-assembled drug delivery systems but 
also in various nano- and microparticulate systems for therapeutic, diagnostic or theranostic purposes. 
Nanoparticles are frequently prepared from biodegradable polyesters such as polylactide (PLLA) or 
polylactide-co-glycolide (PLGA). A simple yet elegant strategy for preparation of MMP-responsive 
nanoparticles was developed by Dorresteijn et al. who synthesized a PLLA based triblock copolymer 
where a MMP-sensitive peptide sequence was introduced as a linker between two PLLA blocks during 
preparation of nanoparticles by emulsion polymerization (Figure 3 A) [91]. The authors showed that 
incubation with MMP2 results in specific enzymatic cleavage of the linker peptide, leading to a 
reduction of the glass transition temperature below body temperature (Figure 3 B) which potentially 
triggers cargo release. MMP-2 expressing C2C12 cells were shown to stimulate release of 5-fluorouracil 
(5-FU) from nanoparticles resulting in comparable cytotoxicity to free 5-FU, while nanoparticles 
prepared with scrambled peptide sequence and loaded with 5-FU remained nontoxic (Figure 3 C). This 
strategy may allow for facile development of custom-designed bioresponsive nanoparticulate delivery 
systems based on triblock copolymers with various peptide sequences. 
Matrix Metalloproteinase Triggered Bioresponsive Drug Delivery Systems – Design, Synthesis and Application 
33 
 
 
Figure 3. (A) Preparation of nanoparticles by nonaqueous emulsion polymerization. Acetonitrile is emulsified in cyclohexane 
in the presence of poly (isoprene)-block-poly (ethylene oxide) (PI-b-PEO) as a stabilizer. Emulsion polymerization of L-lactide 
is initiated by MMP-cleavable peptide with two terminal serine units. Nanoparticles are then transferred inti aqueous solution. 
(B) Incubation with MMP2 results in cleavage of the triblock copolymer and reduction of the glass transition temperature 
below body temperature. (C) Cytotoxicity of 5-fluorouracil (5-FU) loaded nanoparticles in MMP-2 expressing C2C12 cells. 
PLGLAG represents 5-FU loaded nanoparticles with MMP-2 cleavable peptide sequence, LALGPG represents 5-FU loaded 
nanoparticles with scrambled peptide sequence, and PLGLAG w/o 5FU represent unloaded nanoparticles with MMP-2 
cleavable peptide sequence. Reprinted with adaptations from [91] with permission from Wiley. 
As detailed for self-assembled drug delivery systems (Section 2.2.1.), shedding of PEG- or alternative 
polymer shells and/or size reduction of particulate drug delivery systems are common ways to 
incorporate MMP responsiveness into nanoparticulate systems. This concept may be exemplified by the 
study of Grünwald et al., who prepared poly (lactic-co-glycolic acid) (PLGA) nanoparticles with MMP-
sensitive PEG coating for efficient tumor targeting [97]. The targeting strategy relied on long circulation 
half-life of PEGylated particles, passive accumulation of particles in the tumor due to the EPR effect 
and subsequent specific shedding of the PEG corona by tumor-secreted MMPs (Figure 4 A). 
Nanoparticles were prepared from PLGA-b-PEG by nanoprecipitation and concurrently loaded with 
iron oxide nanoparticles. Then, nanoparticles were further modified with PEG via a MMP-sensitive 
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peptide linker. Specific targeting to pancreatic tumor was confirmed by Prussian Blue staining of 
nanoparticles (Figure 4 B) and MMP-9 dependent uptake was verified in vivo using Mmp9 deficient 
mice (Figure 4 C). 
 
Figure 4. (A) Schematic of MMP-9 induced in vivo de-shielding of nanoparticles. (B) Uptake of nanoparticles into pancreatic 
tissue without and with tumors. Nanoparticles (arrows) were stained by Prussian blue. Scale bar represent 100 µm. (C) Uptake 
of nanoparticles into pancreatic tissue in the presence and absence of tumor or MMP-9, respectively as determined by Prussian 
blue staining-based counting. Reprinted with adaptations from [97] with permission from Elsevier.  
Similarly, Gullotti et al. prepared PTX loaded PLGA nanoparticles, which were coated with 
polydopamine and modified with CPP and a PEG-MMP-sensitive peptide conjugate [98]. The authors 
confirmed MMP dependence of cellular uptake in vitro. However, they also noted that premature drug 
release from PLGA nanoparticles, which was virtually independent from surface modification, 
represented a significant issue, which ultimately resulted in statistically insignificant difference of 
cytotoxicicty of MMP-sensitive nanoparticles in the presence and absence of MMP. To overcome this 
problem, covalent conjugation of the cytotoxic drug to the particle matrix via hydrolysable or 
enzymatically degradable linkers was proposed.  
Numerous alternative modification strategies based on shedding of PEG shells have been developed 
with different types of solid nanoparticles. Gold nanoparticles have been widely used, assumingly due 
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to ease of modification and straightforward preparation and imaging. Suresh et al. modified gold 
nanoparticles with a conjugate consisting of PEG and a MMP-sensitive peptide with a terminal cysteine 
for efficient attachment to the surface of gold nanoparticles [99]. The modified particles were stabilized 
by the PEG shell but formed larger aggregates after treatment with MMP. Cellular uptake of gold 
nanoparticles was up to 100-fold increased after incubation with MMP compared to uptake of particles 
with non-cleavable PEG shell. Nazli et al. used iron oxide nanoparticles as a template for MMP-
triggered release of DOX [100]. Iron oxide nanoparticles were coated with an MMP-sensitive PEG 
hydrogel shell via surface-initiated photopolymerization and modified with an integrin binding motif. 
Doxorubicin was loaded into the hydrogel shell by soaking. Interestingly, this design resulted in MMP-
dependent drug release with 60% DOX release in the presence of MMP and 36% release in its absence. 
Furthermore, active targeting through integrin binding resulted in improved cellular uptake in tumor 
cells. With this approach, the authors showed that targeted intracellular delivery of cytotoxic drugs by 
nanocarriers and intracellular MMP-dependent drug release could be successfully combined. A facile 
and simple approach to MMP-sensitive PEGylation of nanoparticles was developed by Choi et al., which 
relied on layer-by-layer (LbL) assembly instead of chemical conjugation [101]. Heparin-Pluronic 
nanogels were used as template nanoparticles onto which multiple layers of poly (ethylenimine) (PEI) 
and heparin were deposited. As a final layer, a PEI-MMP sensitive peptide-PEG conjugate was 
employed. The authors showed that this approach resulted in MMP-dependent improvement of cellular 
uptake of nanoparticles in vitro. In principle, this LbL coating strategy could be used as a straightforward 
and simple platform to incorporate bioresponsive elements into drug delivery systems. LbL coating can 
be applied with alternative materials as well (e.g. polyester-based nanoparticles), especially if the 
nanoparticle surface is negatively or positively charged.  
The general concept of using MMPs to trigger a reduction of particle size was also applied using gelatin 
nanoparticles since MMP-2 and MMP-9 not only hydrolyze specific peptide sequences but also 
efficiently degrade gelatin. As an example, Wong et al. used 10 nm quantum dots as model nanoparticles 
for encapsulation into 100 nm gelatin nanoparticles [102]. Gelatin nanoparticles were efficiently 
degraded in vitro and in vivo in the presence of MMP-2, releasing quantum dots and resulting in 
improved interstitial transport within tumor tissue after intratumoral injection. A more complex drug 
Matrix Metalloproteinase Triggered Bioresponsive Drug Delivery Systems – Design, Synthesis and Application 
36 
 
delivery system for MMP-sensitive release of DOX modified gold nanoparticles from gelatin 
nanoparticles was developed by Ruan et al. (Figure 5) [103]. In this case, PEG- and DOX-modified 
gold nanoparticles were attached onto gelatin nanoparticles, which were hydrolyzed in the presence of 
MMP-2, releasing drug-loaded gold nanoparticles. This design was developed to allow long circulation 
and accumulation in the tumor using the EPR effect. Within the tumor tissue, gold nanoparticles are 
released by MMP leading to improved transvascular and interstitial distribution. Gold nanoparticles 
were modified with DOX via a pH labile hydrazine bond, allowing release of free DOX only in the 
acidic microenvironment of the tumor and/or within lysosomes after cellular uptake. 
 
Figure 5. (A) Schematic of drug delivery system design. Gold nanoparticles were modified with DOX via pH labile hydrazine 
bond and with PEG. Gelatin nanoparticles were prepared and decorated with modified gold nanoparticles via EDC/NHS 
chemistry. (B) Schematic of delivery strategy. Nanoparticles extravasate at tumor site via EPR effect, MMP activity degrades 
gelatin nanoparticles and releases modified gold nanoparticles. Modified gold nanoparticles show improved interstitial 
penetration of tumor tissue and DOX is released after cleavage of hydrazine bond in the acidic tumor microenvironment or 
after cellular uptake of gold nanoparticles in the lysosomal compartment. Reprinted from [103] with permission from Elsevier. 
Expression of MMP may also be exploited for active targeting of nanoparticles to the site of disease or 
to specific cells. As detailed in Section 2.2.1. such active targeting to MT-MMP has been applied in the 
case of targeted treatment after myocardial infarction. Similarly, glioblastoma is signified by 
overexpression of MT1-MMP on angiogenic blood vessels as well as glioma cells. Gu et al. therefore 
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designed PEG-PLA nanoparticles decorated with a peptide with high binding affinity to MT1-MMP 
[104]. Nanoparticles were also modified with iRGD, facilitating binding to the tumor vasculature, 
extravasation and tumor tissue penetration. Targeted nanoparticles were loaded with PTX and compared 
to non-targeted PTX loaded nanoparticles and Taxol. The targeted nanoparticles showed improved 
antiproliferative activity, higher apoptosis rate and stronger inhibition of glioma spheroid growth in 
vitro. Finally, targeted nanoparticles with iRGD modification resulted in longest survival of glioma 
bearing mice. Another nanoparticle design for glioma targeting was proposed by Locatelli et al. [105]. 
In this study, polymeric nanoparticles were loaded with Alisertib, a selective aurora A kinase inhibitor, 
and silver nanoparticles as cytotoxic drug payload and modified with a MMP-2 targeting peptide. 
Despite showing some effect on cell viability in vitro and tumor growth in vivo, unfortunately MMP-2 
dependent accumulation or targeting was not directly confirmed in this study, especially due to the lack 
of untargeted controls. 
Finally, numerous studies use MMP-specific responsive systems for diagnostic and theragnostic 
purposes. Exemplary theragnostic systems based on MMP activity are drug loaded gold nanoparticle 
assemblies developed by the group of Yoo [106, 107]. In both cases, MMP-2 cleavable peptides were 
employed for crosslinking of modified gold nanoparticles into nanoclusters. Drug loading was achieved 
either through thiolation of DOX followed by direct loading onto gold nanoparticles or through covalent, 
pH-sensitive attachment onto the PEG shell of gold nanoparticles. Modified gold nanoparticles were 
then crosslinked either directly via MMP sensitive peptides or via peptide-modified quantum dots. Both 
systems were specifically disassembled in the presence of MMP-2 and released DOX under reducing 
conditions in the cytosol or in acidic environment of the tumor tissue or lysosomes. The quantum dots 
incorporated in the theragnostic system can be either employed for traditional fluorescence imaging or 
can be used in conjunction with gold nanoparticles for Förster resonance energy transfer (FRET) [107]. 
The alternative approach of solely using gold nanoparticle presented later is advantageous with regards 
to toxicity associated with quantum dots but still allows in vivo imaging by computer tomography [106]. 
Lastly, an entirely different and novel approach on using MMP responsive elements for diagnostic 
purposes was recently published by Ritzer et al. [108]. In this study, the authors modified microparticles 
with bitter substances using a MMP sensitive peptide as linker. Microparticles were incorporated into 
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chewing gum to generate a diagnostic device, which uses the tongue as a sensor and therefore allows 
diagnosis by “anyone, anywhere, anytime”. Sensing of bitter taste is linked to the detection of poisons, 
which potentially explains why bitter substances are very sensitively recognized, some substances even 
in the nanomolar range. The design of the diagnostic system ensured that in the absence of MMP, bitter 
substances remained attached to the microparticles and therefore were not detectable. However, in the 
presence of elevated MMP levels, e.g. due to peri-implant disease, periodontitis or gingivitis, peptide 
linkers were cleaved and low molecular weight, water soluble, bitter substances were released which 
could be immediately detected by the bitter sensors of the tongue. 
In conclusion, MMP sensitive particulate delivery systems have evolved and diversified significantly in 
the last decade. Based on our analysis, the most widely employed strategy for incorporation of MMP 
responsiveness was based on using MMP sensitive linkers to induce shedding of PEG shells or structural 
transition upon linker cleavage by MMP. Numerous authors developed particulate systems, which 
showed prolonged circulation due to the presence of a stable, hydrophilic (PEG-) shell and appropriate 
particle size distribution. Frequently, passive targeting to the tumor was achieved utilizing the EPR 
effect. After extravasation, MMP activity resulted in de-PEGylation and/or other structural transitions, 
resulting in improved interstitial penetration, deposition within the tissue and/or cellular uptake. Apart 
from this general design, frequently additional elements, such as active targeting moieties or CPPs, were 
incorporated to further improve specificity or cellular internalization. Such multifunctional delivery 
systems generated promising results in several studies, especially in the case of addition of CPP [109]. 
With regards to addition of active targeting elements, it still appears to be controversial, and seems to 
depend on the actual indication or use case, if these are advantageous or redundant [81, 82, 104]. It 
should also be reiterated here that besides MMPs enzymatic activity, MMPs have also been successfully 
used as target structures for active targeting of delivery systems. Finally, MMP sensitive system offer a 
plethora of possibilities for diagnostic and theragnostic use. 
2.3. MMP-responsive hydrogels 
Hydrogel-based DDS are ideally suited for local application, e.g. at tumor sites and allow localized, on-
demand drug release, thereby reducing systemic side effects [54]. These systems frequently are 
advantageous concerning their hydrophilicity and biocompatibility and, if properly designed, mimic 
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extracellular matrix (ECM) structure, providing the natural environment for cell invasion and 
proliferation. These processes are tightly associated with MMP activity. Therefore, addition of MMP 
responsive elements may be regarded a logical and straightforward choice for hydrogel-based tissue 
engineering scaffolds and drug delivery systems alike. Hyaluronic acid, a non-sulfated 
glucosaminoglycan, is a major component of the ECM and abundantly present in load-bearing joints 
due to its viscoelastic properties. Its biocompatibility, biodegradability and hydrophilicity has attracted 
significant attention as a matrix for drug delivery of sensitive drugs [110]. Hydrogels composed of low 
molecular weight hyaluronic acid and MMP sensitive peptide crosslinkers were developed by Kim et 
al. for tissue defect regeneration [111]. While in this case no drug was encapsulated into the hydrogels, 
the authors showed that mechanical properties as well as degradation rate of the hydrogels could be 
tailored by hyaluronic acid molecular weight and MMP sensitivity of crosslinking.  
Purcell et al. achieved MMP-responsive delivery of recombinant tissue inhibitor of MMPs (rTIMP-3) 
from an injectable hydrogel consisting of modified hyaluronic acid and modified dextran sulfate [112]. 
Modification of the polysaccharides was such that both components could be crosslinked directly as 
well as via MMP sensitive peptide linkers. Recombinant TIMP-3 was encapsulated within the hydrogel 
through electrostatic interactions with modified dextran sulfate and was released in response to matrix 
degradation in the presence of elevated MMP levels. The design of this delivery system thus introduces 
a feedback loop where elevated MMP levels result in increased release of rTIMP-3, which itself inhibits 
MMP activity. Therefore, this “intelligent” drug delivery system results in on-demand, well-regulated 
release as opposed to the majority of simpler bioresponsive delivery systems. 
An alternative strategy for the generation of MMP-responsive hydrogels for drug release relies on 
natural or semi-synthetic matrices such as gelatin. Sutter et al. modified a recombinant gelatin derivative 
with methacrylate residues for crosslinking and encapsulated lysozyme and trypsin inhibitor as model 
proteins [113]. Release of the model drugs was found to be primarily diffusion-controlled and to depend 
on hydrogel mesh size and degree of gel swelling. Degradation of hydrogels was also investigated in 
the presence of MMP-1 and MMP-9. While no hydrogel degradation occurred with MMP-9, MMP-1 
resulted in complete degradation within 5 days. However, unfortunately in this study release of model 
drugs was not investigated in the presence of MMP.  
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Drug release from in situ forming, poly (ethylenoxide)-poly (propylenoxide)-poly 
(ethylenoxide)triblock copolymer (Pluronic®) based, MMP sensitive hydrogels was investigated by 
Garripelli et al. [114]. Pluronic thermogels can be tailored to display gelation temperatures in the range 
of body temperature and hence, can be applied as a liquid while gel formation immediately takes place 
at elevated temperature. PTX was incorporated into the thermogels as a model drug. Drug release from 
MMP sensitive hydrogels was slow in the absence of MMP but increased dramatically in the presence 
of MMP. 
Another example for localized application of MMP-sensitive hydrogels is focused on myocardial 
infarction, which is characterized by limited intrinsic regeneration and a high mortality rate [115]. 
Kraehenbuehl et al. developed an injectable MMP-sensitive hydrogel, delivering the pro-angiogenic and 
pro-survival factor thymosin β4 (Tβ4) along with human embryonic stem cells (hESC) to infarcted 
myocardium of rats [115]. In situ gel formation from liquid 8-arm PEG-vinylsulfone precursors occurred 
after minutes during surgery, allowing injection in the liquid form. In vivo release of Tβ4 was observed 
over a period of 6 weeks. After six weeks rats treated with the combination Tβ4 and hESC showed better 
aligned cardiomyocytes in the infarcted zone compared to PBS treated rats.  
In summary, hydrogel systems for localized therapy show numerous advantages: they reduce systemic 
side effects while maximize local drug concentration and require less complicated designs compared to 
particulate delivery systems. MMP sensitive elements have been successfully used to introduce on-
demand drug or even stem cell release. Notably, the MMP-sensitive release of MMP inhibitors from 
hydrogels results in a feedback-loop that might be used to further improve therapy, especially in cases 
were a well-balanced reduction of MMP activity is essential. 
2.4. MMP-sensitive nucleic acid delivery 
Nucleic acid (NA) delivery represents a specific challenge for drug delivery systems since nucleic acids 
not only must be protected from degradation, e.g. by nucleases, during delivery but must also be 
delivered into the cytosol (e.g. siRNA) or nucleus (e.g. plasmid DNA) [54]. These challenges are 
addressed by specialized delivery systems such as non-viral gene delivery systems that, on the one hand, 
encapsulate or complex NAs to offer protection from degradation and, on the other hand, ensure cellular 
uptake. However, requirements regarding sufficient circulation time, active or passive targeting, 
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biocompatibility and potentially bioresponsiveness are broadly comparable to delivery systems for 
chemical or biological drugs. For this reason, strategies discussed above for MMP triggered structural 
changes, such as shedding of PEG shell, resulting in improved tumor uptake by the EPR effect and 
efficient distribution within the tumor tissue are also applied for NA delivery system. Furthermore, 
inclusion of CPPs to improve cellular uptake as well as MMP triggered unshielding of these moieties 
are frequently applied in the context of MMP sensitive NA delivery. The system developed by Wang et 
al. represent an excellent example, combining MMP induced structural changes, i.e. shedding of the 
PEG corona of micelles with CPP in a NA delivery system [116]. The chemical structure of this system 
and the general concept is illustrated in Figure 6. A block copolymer from PEG and PCL is used as the 
amphiphile, enabling self-assembly of micelles. The two blocks are connected via a peptide sequence 
containing an MMP-sensitive element and a polycationic polyarginine element for complexation of 
siRNA and for improved penetration of target cell membranes. A similar system was developed by 
Veiman et al. using stearylated peptides containing polyarginine repeats, which were PEGylated via a 
MMP-sensitive linker [117]. Another micellar siRNA carrier system used dimethylaminoethyl 
methacrylate (DMAEMA) as charged building block for siRNA condensation and a terpolymer block 
resulting in pH-responsive, endosome disruption [118]. Again, PEG was attached via MMP-cleavable 
linker resulting in improved circulation time and masking of the polycationic and membrane disruptive 
elements of the micelles. The authors showed that in the presence of elevated MMP levels zetapotential 
of nanoparticles increased due to shedding of the PEG corona and release from endosomal compartment 
was improved due to the core forming terpolymer block. 
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Figure 6. (A) Chemical structure of block copolymer consisting of PEG and PCL with a MMP-2/9 degradable linker 
(PLG*LAGr9) which contains a poly arginine repeating sequence for siRNA complexation and membrane penetration. (B) 
Schematic function of the delivery system showing long term circulation, extravasation at the tumor site, MMP triggered 
shedding of the PEG corona, cellular uptake and delivery of siRNA into the cytosol. (C) In vivo inhibition of MDA-MB-231 
tumor xenograft growth in mice and (D) expression of Plk1 mRNA in tumors 48 hours after the last injection. MSNP: MMP-
sensitive micellar nanoparticles; USNP: MMP-insensitive micellar nanoparticles; siN.C. negative control siRNA; siPlk1: 
siRNA targeting Plk1 mRNA. Reprinted with adaptations from [116], with permission from Elsevier. 
Several authors investigated co-delivery of low molecular weight chemical drugs and NA, mainly 
targeting at tumor therapy. In this regard, the delivery platform must accommodate both NA and 
chemical drugs, e.g. by combining neutral lipids with polycations. Zhu et al. approached this challenge 
by synthesis of a conjugate consisting of PEI modified with PEG via MMP-cleavable peptide linker and 
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modified with dioleoylphosphatidylethanolamine (DOPE) [119]. This conjugate self-assembled into 
nanoparticles encapsulating PTX in its lipidic core and complexing siRNA with PEI, while the 
outermost layer consisted of a MMP-responsive PEG shell. Combining PTX with anti-survivin siRNA 
with a MPP-sensitive delivery system proved to be an efficient strategy, resulting in IC50 value of 96 
nM for PTX alone, 28 nM for PTX loaded nanoparticles and 15 nM for PTX and siRNA loaded 
nanoparticles. Salzano et al. also combined a chemotherapeutic drug (DOX) with NA (miRNA-34a) in 
a single delivery system [120]. However, in this case several different conjugates were synthesized and 
assembled into nanoparticles (Figure 7A). The authors combined MMP-sensitive DOX release 
(PEG2k-CLV-Dox) with reduction-sensitive release of miRNA (miRNA-34a-S-S-PE) and a CPP 
conjugate (TAT-PEG1k-PE) to form self-assembled micellar nanoparticles. Again, the authors showed 
that the combination of DOX and miRNA was more effective than each single treatment, both in 2D 
monolayer culture (Figure 7 B) and in a 3D spheroid tumor model (Figure 7 C). 
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Figure 7. A) Schematic representation of the structure of the individual conjugates as well as the hypothetical structure of the 
self-assembled nanoparticle. B) Cell viability 2D cell culture after treatment with different formulations. C) Cell viability in 
3D spheroid model after treatment with different formulations. Reprinted with adaptations from [120], with permission from 
Wiley.  
MMP responsive elements have also successfully been used for localized, on-demand delivery of DNA 
and siRNA from nanofibrous matrices for treatment of diabetic ulcers in a series of papers by Kim et al. 
[121-123].  Diabetic ulcers are characterized by a disbalance in remodeling of ECM accompanied with 
elevated MMP levels. Therefore, the authors focused on local delivery of NA, either silencing 
overexpression of MMP [122] or delivering genes for growth factor expression [121]. The matrix was 
produced by electrospinning of polycaprolactone-polyethylene glycol (PCL-PEG) block copolymer, 
whose surface was modified with a conjugate consisting of MMP-sensitive peptide and PEI. DNA or 
siRNA was then electrostatically bound to PEI. Once the MMP-sensitive peptide is cleaved, NA/PEI 
nanoparticles are released and are endocytosed by the wound bed. Here, chemical immobilization on 
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the surface allows for homogenously distributed, well-accessible agents and attenuated release linked 
with physiological signals (inflammation, growth factors). In the absence of MMP, release of NA/PEI 
complex remained low, only a part was adsorbed on the surface and was released by simple diffusion. 
Significant higher release rate could be achieved in presence of MMP (approximately 47 % compared 
to 15 % without MMP). In an in vivo study in cutaneous wounds of streptozotocin-induced diabetic 
mice MMP-sensitive meshes for NA delivery showed the best healing results and the highest hEGF 
expression up to 14 days meaning that a single treatment was already sufficient [121]. 
In summary, MMP responsive elements have been successfully applied for nucleic acid delivery, both 
for systemic as well as local application. In addition to the general design strategies outlined above, NA 
delivery systems are characterized by additional polycationic elements that ensure proper complexation 
of NA and improve cellular uptake. 
4. Challenges in synthesis and incorporation of MMP-sensitive peptides into drug delivery 
systems 
Despite the numerous successful designs described in the preceding sections and the numerous 
advantages of inclusion of bioresponsive elements, the identification of suitable MMP-cleavable 
peptides and their incorporation into drug delivery systems remains challenging.  
The first step in the development of MMP-sensitive drug delivery systems is to evaluate which MMP is 
specifically overexpressed and overactive in the particular tissue or disease state. A specific MMP may 
represent a target for one disease but counter target for another disease and additionally, some MMPs 
have similar substrate specificity (e.g. MMP-2 and MMP-9) [55]. Knowledge of the cleavage site is 
therefore highly important. Interestingly, the structural features of the cleavage site are similar for all 
MMPs, containing a zinc ion in the catalytic domain and a deep S1’ pocket as docking point [124]. In 
general, the peptide linker itself should be rapidly cleaved once the DDS reaches the target site. These 
linkers can be rationally designed based on the literature [125-128]. One approach to identify protease 
cleavage sites is the proteomic identification of protease cleavage sites (PICS) method [129]. This 
method employs proteome-based peptide libraries and allows identification of prime and non-prime 
cleavage sites within one single experiment, enabling high throughput approaches, e.g. identification of 
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4300 cleavage sites of nine MMPs. The main advantage of this method is the specificity profiling 
without any knowledge of structure, sequence preferences or the physical role of MMP [126]. Once the 
targeted MMP is identified and a desired set of MMP-sensitive linkers is chosen, enzyme kinetic studies 
should be conducted in order to ensure appropriate catalytic efficiency. Such studies were performed by 
Patterson and Hubbell for MMP-responsive PEG hydrogels [130]. The authors investigated degradation 
kinetics (kcat) of 17 different MMP-1 and MMP-2 substrate peptides both in solution and after 
incorporation into hydrogels. Variation of MMP substrate sequence strongly affected hydrogel 
degradation, cell spreading and cell invasion in vitro, allowing tuning of hydrogel degradation 
characteristics. As a last step in the selection of a MMP-specific linker, the selectivity should be 
investigated for a successful targeting approach, since the cleavage of the linker by other enzymes would 
lead to unspecific drug release and potential side effects [55].  
The incorporation of MMP-sensitive peptides itself but also the interaction between MMP, drug delivery 
system and drug require additional scrutiny. The active site of MMP is predominantly negatively 
charged [131, 132], which might lead to charge repulsion with negatively charged DDS scaffold. 
Besides such accessibility issues of MMP substrate to MMPs catalytic domain, the MMP itself in 
numerous cases must diffuse into drug delivery systems, hence mesh size and rigidity of DDS play an 
important role. Furthermore, mild synthesis conditions are frequently required to protect the integrity 
and therapeutic efficacy of the drug molecule. But, conjugates should also show sufficient stability, fast 
cleavage and generate biocompatible cleavage products [63]. Lastly, the drug should stay active after 
cleaving from the MMP-sensitive peptide even though some amino acids might remain linked to the 
drug.  
Different synthetic options for incorporation of the peptide into the drug delivery system or between the 
drug and the drug delivery system via covalent conjugation have been published. One possibility is 
Michael addition, the nucleophilic addition to an α,β-unsaturated carbonyl compound. Tauro et al. used 
the sulfhydryl group of cysteine as nucleophile and acrylate group as unsaturated carbonyl compound, 
yielding 74.1 to 76.1 % efficiency after overnight incubation [133]. However, such reaction scheme 
might result in peptide dimerization due to disulfide formation as well as other side reactions, overall 
low drug loading and nonspecific release [134, 135]. Side reactions and disulfide formation can be 
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largely eliminated by introducing the MMP-sensitive peptide using EDC (1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide)/NHS (N-hydroxysuccinimide) chemistry [135]. In addition, this 
coupling chemistry produces water soluble by-products that can be easily removed via gel-filtration or 
dialysis. Braun et al. used the EDC/NHS chemistry to couple a myostatin inhibitor via MMP-sensitive 
peptide to poly (methyl methacrylate) microparticles [136].  This strategy lead to high incorporation 
efficiency after 2 hours of incubation. However, one disadvantage of this method is the relative non-
specificity, leading to random coupling of primary amino groups with carboxyl groups. This can, on the 
one hand, result in self-polymerization leading to covalent aggregates and increasing the risk of an 
immunological response, and on the other hand, in a heterogeneous outcome with unclear stoichiometry 
[136, 137]. Maleimide coupling can be conducted between primary amines and thiols. This approach 
shows a lot of potential for biomolecules, carrying a free thiol or amine group. The disadvantage of this 
method is the hydrolysis of the maleimide ring over long reaction times and increasing pH (pH ≥ 8) [75, 
138] . Finally, numerous authors used click chemistry, also known as copper (I)-catalyzed azide-alkyne 
cycloaddition (CuAAC), to synthesize peptide-carrier- or drug-peptide-carrier conjugates [86, 136, 
139]. Due to their specific properties (weak acid/base) the functional group, namely alkyne and azide 
groups, are mostly inert towards biological molecules and the reaction can be carried out under broad 
reaction conditions (pH 4-12, aqueous solution, 0-120 °C) [137, 140]. The main disadvantage of CuAAC 
is the use of copper as a catalyst. Although the human body is in need of copper to function, excessive 
intake can lead to different diseases (kidney diseases, Alzheimer’s disease, hepatitis) [140]. 
Besides the covalent binding, physical interactions (electrostatic and hydrophobic interactions) represent 
another option, having the advantage that biomolecules do not have to be modified. However, these 
conjugations are frequently less easy to control, less stable and less reproducible compared to covalent 
binding. Tauro et al. complexed cisplatin to aspartic acid residues of MMP-sensitive spacer, binding the 
chemotherapeutic drug to the hydrogel matrix [133]. Complexed cisplatin was slowly released even in 
the absence of MMP, indicating that complexation was successful but not sufficient to achieve full 
retention (50 % release within the first 24 h). When cisplatin was only entrapped into hydrogels, 95 % 
was released within one hour, showing that by complexation the release could be retained but not fully 
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controlled. After addition of MMP to the drug delivery system, cisplatin was released at an accelerated 
rate.  
Aside from the conjugation strategy, the possible interaction of the carrier and MMP may play an 
important role. To gain insights into these effects, Chau et al. varied the charge of carboxymethyl 
dextran, coupled via MMP-sensitive linker to methotrexate, by reacting with ethanolamine under 
different conditions [141]. The charge had significant influence on the cleavage rate by MMP-2, 
resulting in more efficient cleavage if the negative charge of carboxymethyl dextran was masked. On 
the other hand, enzymatic digestion rate by MMP-9 was insensitive to dextran charge [141]. If the MMP-
sensitive peptide is incorporated into a 3-D matrix, the MMP must diffuse into the matrix to cleave the 
peptide. In order to understand the influence of mesh sizes of hydrogels, Ross et al. compared poly 
(ethylene glycol) diacrylate (PEGDA) with different molecular weights (3.4, 10 and 20 kDa) and 
different concentrations, resulting in mesh sizes between approx. 5 to 20 nm [142]. PEGDA hydrogels 
of 3.4 kDa produced mesh sizes smaller than the dimensions of MMP-2 (9.75 nm length by 6.75 nm 
breadth) and therefore prohibited the diffusion of MMP-2 into the hydrogel and release of the model 
drug [133, 142]. No significant difference between model drug release was observed for 10 and 20 kDa 
PEGDA, potentially due to the inability of acrylate groups to form further crosslinks due to the 
increasing viscosity and physical restriction after gel formation had started. It can be concluded that 
especially for 3D systems, diffusion of MMP into the hydrogel becomes a key factor for controlled 
release, in addition to the kinetics of peptide cleavage.  
MMP-7 is prone to interact with charged macromolecular surfaces which might influence the stability 
of the catalytic domain [143]. Catalytic activity remained unaffected by the interaction with anionic and 
neutral liposomes, whereas it was impaired in the presence of positively charged liposomes (Figure 8 
A) [144]. If MMP-7 was bound to anionic or neutral liposomes, the active site pocket of the enzyme 
remained accessible (Figure 8 B) and therefore, active, while binding of the cationic liposome lead to 
obstruction of the active site pocket. 
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Figure 8. A) MMP-7 activity in the presence of ○-○ anionic, Δ-Δ neutral, and □-□ cationic liposomes. B) Schematic 
representation of electrostatic surface potentials of MMP-7 with bound hydroxamate inhibitor and its potential interaction 
with anionic and cationic liposomes. Reprinted with adaptations from [144], with permission from Wiley. 
Not only the charge of the carrier and the charge distribution in the enzyme play a vital role, but also the 
constitution of the carrier, meaning the adaptability of the carrier might influence the structural and 
functional integrity of the enzyme. Differently charged liposomes (flexible) were compared to 
differently charged gold nanoparticles (rigid) [143]. The results showed that cationic and anionic gold 
nanoparticles influenced the MMP-7 activity, whereas the former even led to loss of the secondary 
structure of the enzyme. Therefore, besides the charge, rigidity and surface curvature appear to influence 
catalytic binding. Hence, understanding of biological structures of MMP, chemical insertion of MMP-
sensitive peptide and interactions of MMP and the carrier are essential for bioengineering applications. 
5. Utility of MMP responsive elements in the development of commercial products 
Currently, only a few stimuli-responsive nanosystems, i.e. magnetic iron oxide particles (Nanotherm®) 
and thermosensitive liposomes (ThermoDox®), have progressed to clinical phases [145], but no MMP-
sensitive DDS are in clinical trials or on the market. In the case of MMP-sensitive drug delivery systems, 
precise control of the initial response time of the DDS is critical to achieve drug release within the 
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therapeutic window [4]. Response to MMP is not as prompt as the response to other stimuli and 
therefore, the enzymatic specificity and sensitivity to activate the drug delivery systems must be 
optimized [146]. In addition to the basic performance (high sensitivity and selectivity, precise timing of 
the response), clinical performance is a key factor for successful industrial development, this includes 
biocompatibility and biodegradability, stability of the DDS both, during storage and application and the 
ability to scale-up the production to industrial scale [147, 148]. 
6. Conclusions 
The development of MMP responsive drug delivery systems has attracted substantial interest, with 
numerous novel published designs and a plethora of different applications. MMP sensitive drug delivery 
started with comparably simple protease activated prodrugs, which frequently suffered from insufficient 
blood half-life, degradation and premature drug release. Introduction of high molecular weight carrier 
significantly improved circulation time and stability but was limited to highly active drugs. The 
development of particulate drug delivery systems then opened entirely new possibilities with regards to 
loading of different drugs as well as introduction of multiple release mechanisms. In recent years, 
numerous multifunctional drug delivery systems have been developed, e.g. combining MMP sensitive 
elements with penetration enhancers or active targeting moieties. Similarly, MMP sensitive systems 
accommodating different drug types, e.g. cytotoxic, low molecular weight chemical drugs and high 
molecular weight nucleic acids have been developed. Finally, MMP sensitive hydrogels may be 
employed for delivery of stem cells.  
The functionality of MMP sensitive delivery systems strongly depends on optimal incorporation of 
MMP sensitive elements concerning the conjugation to the scaffolds and/or drug, the interaction of 
MMP sensitive elements with scaffold and/or drug and regarding accessibility of those elements to 
MMP. Therefore, designing MMP responsive drug delivery systems requires knowledge of these 
interactions and thoughtful selection and optimization of materials and synthetic strategies.  
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3. Results and Discussion 
3.1. Effects of Degumming Process on Physicochemical and Mechanical Properties of Silk 
Fibroin 
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Effects of silk degumming process on physicochemical, tensile, 
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Abstract 
The removal of sericin from virgin silk (degumming) is the first step in the preparation of regenerated 
silk fibroin for its many applications as biomaterial, in drug delivery or as optical material. The process 
significantly affects the material characteristics of the protein. Degumming of silk is most commonly 
achieved by incubation in sodium carbonate solution at elevated temperature but numerous alternative 
methods employing enzymes, soap, and ionic liquids have been used. Herein, a systematic comparison 
of various degumming methods is provided. Sodium carbonate, sodium oleate, trypsin and 1-butyl-3-
methyl-imidazolium bromide (ionic liquid) were used for degumming of virgin silk and resulting 
materials have been characterized with regards to mass loss, silk fibroin content by amino acid analysis, 
integrity of silk fibroin by size exclusion- and anion exchange chromatography, refractive index, and 
tensile properties. While complete degumming was achieved within 30 minutes using sodium carbonate, 
it was also found that this process resulted in significant reduction of molecular weight, shift towards 
less acidic charge variants and substantial reduction of yield- and rupture strength. Sodium oleate and 
trypsin were inefficient degumming reagents and negatively affected tensile properties. Degumming 
using ionic liquid showed good efficiency and marginal degradation of silk fibroin but also reduced 
yield- and rupture force. The refractive index of silk fibroin did not change by the various degumming 
methods. These results allow rational selection of the degumming method and tuning of silk fibroin 
material characteristics towards specific biomedical applications. 
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1. Introduction 
Silk fibroin (SF), a protein produced by the mulberry silkworm Bombyx mori, has numerous advantages 
as scaffold for drug delivery systems, and for biomaterials. It is biocompatible, biodegradable into non-
toxic products and possesses superior mechanical strength [28, 110]. Not surprisingly, silk fibroin has 
been largely explored as a natural material for various technical and biomedical applications such as 
drug delivery, tissue engineering, biosensors, electronics and optics [149-153]. Silkworm silk fibers 
(bave) consist of a pair of filaments (brin) composed of SF which are coated and held together by the 
glue-like protein sericin. SF consists of a hydrophobic heavy (~370 kDa) and a hydrophilic light (~25 
kDa) chain, connected by a disulfide bond. The heavy chain is formed by highly repetitive crystalline 
fractions, GAGAGS, GAGAGY and GAGAGVGY (Gly-X domains), and responsible for the formation 
of anti-parallel β-sheets [21]. 
For the preparation of drug delivery systems or when intended for human implantation, purification of 
SF is mandatory due to immunogenicity in presence of sericin [154]. This extraction and purification 
process (frequently referred to as degumming) is usually characterized by quite harsh conditions 
(elevated temperature, alkaline pH), resulting not only in sericin degradation but also partial hydrolysis 
of fibroin [155]. Longer degumming in boiling sodium carbonate solution was reported to result in 
reduction of average molecular weight of SF [15, 156]. While degumming using sodium carbonate 
solution is the most common process applied for preparation of silk fibroin for biomedical applications, 
various alternative degumming conditions and processes were published, e.g. degumming with citric 
acid [157], urea [158], tartaric acid [155], different enzymes [17, 159] and ionic liquids [160]. Besides 
the different degumming reagents, different solvents for subsequent dissolution of SF were tested and 
compared, e.g. lithium bromide, Ajisawa’s reagent and formic acid [158, 161] and the influence of 
dissolution time was studied [162]. 
The degumming process conditions are known to primarily affect molecular structure of SF. Besides 
general reduction of average molecular weight depending on degumming time using sodium carbonate, 
it has been found that SF degradation appears to specifically occur in amorphous regions while 
crystalline Gly-X domains are largely unaffected [15, 156]. As a result, formation of beta-sheets is 
virtually unaffected by degumming process duration using sodium carbonate [156]. Besides reduction 
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of molecular weight and despite unchanged beta-sheet formation, changes in the ability to form higher 
order structures were observed [156]. Furthermore, degumming was shown to affect in vitro 
cytocompatibility. SF treated with alkali for extended durations showed inhibitory effects on fibroblast 
cell growth compared to fibroin taken directly from gland [163]. Additionally, the degradation profile 
and drug release kinetics play a key role for the use as scaffold in tissue engineering and drug delivery 
applications. Variation of degumming time was found to affect in vitro degradation and drug release 
kinetics of various model compounds [164]. Recently, we studied the impact of different degumming 
times on the release of differently charged high molecular weight compounds and reported that 
degumming not only influenced SF integrity but also SF charge distribution and hence release of 
charged compounds [156]. Finally, degumming influences SF tensile properties, resulting in reduction 
of failure strength and yield point [16]. 
In summary, degumming process conditions substantially change physicochemical and mechanical 
properties of SF which in turn significantly affects the performance of SF as a scaffold in various 
biomedical applications such as drug delivery and tissue engineering. However, to our knowledge no 
comprehensive study on the effect of different degumming processes and process conditions has been 
performed for regenerated SF in the context of biomedical applications. Therefore, we herein investigate 
the effect of different degumming strategies such as enzymatic and alkali degumming as well as 
degumming using ionic liquid (IL) and process conditions on physicochemical, mechanical and optical 
properties of SF relevant for biomedical applications. 
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2. Materials and methods 
2.1. Materials 
Silkworm cocoons were purchased from Wollspinnerei Vetsch (Pragg-Jenaz, Switzerland). All other 
chemicals were ordered from Sigma Aldrich (Buchs, Switzerland). 
2.2. Methods 
2.2.1. Silk fibroin extraction 
SF was extracted using various degumming reagents and process conditions (Table 1). In brief, SF 
cocoons were cut into small pieces and incubated in the respective solution at 5 g l-1 under constant 
stirring at 300 rpm at the temperature and time as detailed in Table 1. Afterwards, SF fibers were dried 
at room temperature in a fume hood overnight and dissolved in Ajiwasa’s reagent (calcium 
chloride:ethanol:water at a molar ratio of 1:2:8) at 65 °C. The solution was filtered through syringe filter 
with nominal pore size of 5 µm (Yeti PVDF HPLC syringe filter, Infochroma AG, Zug, Switzerland) 
and dialyzed against purified water (Spectra/Por dialysis tubes MWCO 6-8 kDa, Spectrum Laboratories, 
Rancho Domingez, CA, USA). The mass of silk fibroin contained in a known volume of the solution 
was determined gravimetrically after evaporation of water at 65 °C for 24 h. For further processing, all 
silk fibroin solutions were adjusted to 10.0 g l-1.  
Table 1. Degumming reagents and process conditions. 
Sample C5 C30 C60 C120 OL T120 T180 IL 
Degumming 
reagent 
0.02 M 0.02 M  0.02 M  0.02 M  1% 
Sodium 
oleate 
1% 
Trypsin in 
67 mM 
phosphate 
buffer pH 
8 
1% 
Trypsin in 
67 mM 
phosphate 
buffer pH 
8 
90 % 1-butyl-
3-methyl-
imidazolium 
bromide  
Degumming 
time / min  
5 30 60 120 60 120 180 420 
Temperature / 
°C 
100 100 100 100 90 37 37 85 
 
  
Sodium carbonate 
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2.2.2. Scanning Electron Microscopy 
The morphology of differently degummed fibers was studied by scanning electron microscopy (SEM). 
The fibers were sputter coated with gold and characterized with an accelerating voltage of 5 kV using a 
Hitachi TM3030 plus (Hitachi, Krefeld, Germany). 
2.2.3. Mass loss 
Before and after the degumming step the dry mass of the material was determined for 4 individual 
samples (IL: 2 individual samples) and percentage mass loss (m%) was calculated according to equation 
1, where mbefore degumming is the dry mass before and mafter degumming the dry mass after the degumming 
process. 
𝑚% =  
𝑚𝑏𝑒𝑓𝑜𝑟𝑒 𝑑𝑒𝑔𝑢𝑚𝑚𝑖𝑛𝑔−𝑚𝑎𝑓𝑡𝑒𝑟 𝑑𝑒𝑔𝑢𝑚𝑚𝑖𝑛𝑔
𝑚𝑏𝑒𝑓𝑜𝑟𝑒 𝑑𝑒𝑔𝑢𝑚𝑚𝑖𝑛𝑔
∙ 100 %    (1) 
Degumming efficiency based on mass loss was calculated by setting mass loss observed for C120 as 
100% degumming efficiency. 
2.2.4. Amino acid composition 
To determine the amino acid composition, degummed samples (Table 1) were hydrolyzed according to 
USP 41 [165]. In brief, to one gram of degummed sample or sericin (Sericin Bombyx mori, order number 
S5201, Sigma Aldrich, Buchs, Switzerland), 200 µl 6  M hydrochloric acid (containing 0.5 % phenol) 
was added and incubated at 115 °C for 16 h. Hydrochloric acid was removed using speed vacuum. To 
each sample 200 µl 0.02 M hydrochloric acid was added and incubated at 50 °C for 10 minutes. Standard 
solutions with 50, 100, 200, 300, 400, 500, 600 and 1000 µM of amino acids (glycine, alanine, tyrosine, 
serine, glutamic acid, aspartic acid), chosen based on the significant difference in weight percentage 
found in sericin compared to fibroin, were prepared. Samples and standard solutions were derivatized 
using 70 µl borate buffer (pH 8.8), 10 µl sample or standard solution and 20 µl 6-aminoquinolyl-N-
hydroxysuccinimidyl carbamate, vortexed for 10 s and heated at 55 °C for 10 minutes. Then, the samples 
and standards were analyzed by RP HPLC (Agilent 1260 Infinity, Agilent Technologies, Santa Clara, 
CA, USA; Acquity UPLC column, BEH shield RP 18, 1.7 µm, 2.1 x 100 mm, Waters Corporation 
Milford, MA, USA) at 55 °C with a flow rate of 0.4 ml min-1 (gradient steps Table 2). Buffer A consisted 
of a pre-prepared solution of acetonitrile, formic acid and 100 mM ammonium formate (10:6:84), which 
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was diluted with water (5:95). Buffer B consisted of acetonitrile and formic acid (98:2). The proportion 
of sericin and fibroin in the samples was calculated by setting SF 120 as 100 % fibroin and sericin to 
0% fibroin. Degumming efficiency was calculated based on SF content by setting cocoons to 0% 
degumming efficiency and SF 120 to 100 % degumming efficiency. 
Table 2. RP HPLC step gradients. 
Time / min Buffer A / % Buffer B / % 
0 99.9 0.1 
0.54 99.9 0.1 
5.74 90.9 9.1 
7.74 78.8 21.2 
8.04 40.4 59.6 
8.64 40.4 59.6 
8.73 99.9 0.1 
9.5 99.9 0.1 
2.2.5. Size exclusion chromatography 
The chromatographic system (Agilent 1260 Infinity, Agilent Technologies, Santa Clara, CA, USA) used 
for size exclusion chromatography (SEC) was equipped with a quaternary pump, auto sampler, column 
oven, diode array detector (DAD) and a static and dynamic light scattering detector (SLS and DLS). 
The separation was performed using an Agilent Bio SEC-3 column (3 µm, 300 Å, 4.6 x 300 mm, Agilent 
Technologies, Santa Clara, CA, USA) with 0.1 M sodium chloride as mobile phase and a flow rate of 
0.3 ml min-1 at 30 °C. 
2.2.6. Weak anion exchange chromatography 
For weak anion exchange chromatography (WAX) the same chromatographic system as for SEC was 
used. The separation was performed using a Bio WAX ion-exchange column (3 µm, 4.6 x 150 mm, 
Agilent Technologies, Santa Clara, CA, USA) with step gradients (Table 3). Buffer A consisted of 
20 mM tris-(hydroxymethyl)-aminomethan (Tris) pH 8.5 and buffer B 20 mM Tris and 2 M sodium 
chloride pH 8.5. The separation was performed with a flow rate of 0.5 ml min-1 at 30 °C. 
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Table 3. Weak anion exchange chromatography step gradients. 
Time / min  Buffer A / % Buffer B / %  
5 100 0 
5.01 80 20 
10 80 20 
10.01 60 40 
15 60 40 
15.01 40 60 
20 40 60 
20.01 0 100 
2.2.7. Tensile testing 
Single silk baves were unreeled from cocoons mounted into steel frames and degummed according to 
Table 1. To avoid batch-to-batch variability, one cocoon was unreeled and samples, taken from this 
cocoon, were measured in triplicates. Afterwards, degummed fibers were rinsed with water and dried in 
a fume hood over night. Then the frames with the fibers were fixed in a Texture Analyser TA-XT2i 
(Stable Microsystems Ltd., Surrey, UK) with grips and the frames were opened laterally to allow 
pulling. Test speed was set to 0.17 mm s-1 until rupture of the fibers.  
2.2.8. Ellipsometry 
Silicon wafers (2.25 cm2, thick
Germany) were washed with acetone and ethanol (ultrasound (SW 3 by Sonoswiss AG, Ramsen, 
Switzerland) each 15 min) and cleaned with carbon dioxide snow. Overcoats of silk fibroin of various 
degumming times and concentrations were prepared by spin casting the fibroin solutions onto the SiO2 
surface at a spin speed of 4000 rpm for 40 s (WS 650-MZ-23NPPB, Laurell Technologies Corporation, 
North Wales, USA). The samples were dried under vacuum in a desiccator over CaH2 for at least 3 h. 
To induce β-sheet formation, samples were placed in methanol for 15 min and again dried under vacuum 
in a desiccator over night. 
The refractive indices of dry silk fibroin films on silicon wafers were measured using an alpha-SE 
Ellipsometer (J. A. Woollam, Lincoln, USA). Experimental data were modelled by the Cauchy fit for 
transparent films using the software Complete EASE, Version 5.19, choosing 1.50 as starting point for 
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the fit of the refractive index of the protein. Refractive index measurements were taken at three different 
angles (65°, 70°, 75°) on three different spots on each film, and the measurements were repeated on 10 
different films of each sample. 
2.2.9. Statistical analysis 
All measurements were performed in triplicates unless stated otherwise and results are presented as 
mean ± standard deviation. Two-tailed Student’s t-test or one-way ANOVA with Tukey´s test (mass 
loss, SF content) or Dunnett’s test (amino acid composition, untreated cocoons as control) was 
performed to identify statistical significance. Probability values of p ≤ 0.05 were considered statistically 
significant. 
3. Results 
3.1. Microscopic characterization 
Scanning electron micrographs of individual fibers after degumming were recorded to visually evaluate 
the removal of sericin as well as the microstructure of SF filaments (Figure 1 A-I). The native, untreated 
bave (Figure 1 A) showed two fibroin filaments, which are coated with and connected by sericin. After 
degumming using sodium carbonate (Figure 1 B-E), filaments without sericin coating were found and 
after extended degumming duration fibril formation at the surface of individual filaments was observed 
(Figure 1 C and E). After treatment with sodium oleate (Figure 1 F) filaments were partly disconnected 
and spots were visible on the filament surface, likely representing sericin residues. After enzyme 
treatment with trypsin for two and three hours (Figure 1 G and H), the fiber appeared cracked with a 
puckered surface. Degumming with ionic liquid (Figure 1 I) resulted in filaments, which partly 
appeared to be still connected and coated with sericin, and spots were visible on the fiber surface. Figure 
S1 in supporting information provides additional micrographs of the samples after degumming.  
3.2. Mass loss 
SF degumming efficiency was assessed by the mass lost during the degumming process (Figure 1 J and 
K). However, it should be highlighted that mass loss during degumming may represent sericin and 
fibroin degradation. Mass loss may therefore be indicative of efficient removal of sericin but excessive 
mass loss may indicate substantial hydrolysis of fibroin. Sodium carbonate treatment resulted in overall 
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highest mass loss and highest degumming efficiency, whereas the degumming with sodium oleate lead 
to the lowest mass loss. Within the different degumming times with sodium carbonate, treatment for 
5 minutes resulted in significantly lower mass loss than longer degumming times. No statistically 
significant difference was observed for mass loss for C30, C60 and C120. Treatment with trypsin 
resulted in statistically significantly higher mass loss than sodium oleate treatment. Incubation with 
trypsin for 2 or 3 hours lead to similar mass loss with statistically insignificant differences between the 
incubation times. Ionic liquid degumming lead to statistically insignificant different mass loss as 
treatment with trypsin and was also similar to C5. 
 
Figure 1. (A-I) Scanning electron micrographs of native and degummed fiber samples. (A) native silk fiber, (B) C5, (C) C30, 
(D) C60, (E) C120, (F) OL, (G) T120, (H) T180 and (I) IL. Bar in (A) represents 20 µm and applies to all micrographs. (J) 
Mass loss during degumming process and (K) degumming efficiency calculated based on mass loss. Asterisks indicate 
significance level: ** p ≤ 0.01; p ≤ 0.001. 
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3.3. Amino acid composition 
Amino acid composition was determined focusing on glycine, alanine, tyrosine, serine, aspartic acid and 
glutamic acid because the amino acid content differed significantly between in SF and sericin (Figure 
2 A and B). Glycine content differed significantly between cocoon and sericin. All degummed samples 
showed statistically significantly higher glycine content than untreated cocoon due to partial or complete 
hydrolysis of sericin. Similarly, statistical significant differences in alanine content were found between 
untreated cocoons and sericin as well as degummed samples except OL and IL. Variation of tyrosine 
content between cocoons and sericin was rather small but significant. Major differences between 
cocoons and sericin as well as degummed samples were observed in serine content. Serine content in 
all degummed samples was significantly lower than in cocoons, again confirming partial or complete 
hydrolysis of sericin. The same was found for aspartic acid and glutamic acid.  
Determination of the amino acid composition allowed calculation of fibroin content and degumming 
efficiency (Figure 2 C and D). Fibroin content was statistically significantly higher than in cocoons for 
all degummed samples except OL. No significant differences were observed for fibroin content after 
treatment with sodium carbonate for different durations or fibroin content after treatment with trypsin 
for different durations. Since fibroin content in untreated cocoons was already approx. 80 %, differences 
between the degumming processes are more evident if degumming efficiency is assessed (Figure 2 D). 
Complete degumming is observed after 30 minutes treatment with sodium carbonate. Incomplete 
degumming is found only after treatment with sodium oleate and to a smaller extend trypsin for 2 hours. 
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Figure 2. Amino acid content for (A) glycine, alanine, tyrosine and (B) serine, aspartic acid and glutamic acid of cocoons, 
sericin and degummed samples. Fibroin content (C) and degumming efficiency (D) of cocoons and samples as calculated based 
on amino acid composition analysis. 
3.4. Size exclusion and weak anion exchange chromatography 
Silk cocoons showed a single peak at 5.6 minutes in size exclusion chromatography using UV detection 
(Figure 3 A). With longer degumming time in sodium carbonate (C5, C30, C60 and C120) the main 
peak became smaller and a second broad peak appeared at longer retention times (lower molecular 
weight). In addition, a small leading peak was observed at approx. 5.0 minutes. OL exhibited similar 
results compared to cocoon sample but in addition a small shoulder appeared at approx. 5.4 minutes. 
T120 and T180 did not show peaks at the same position as the other samples, but peaks at longer 
retention times were observed. IL exhibited a similar chromatogram as untreated cocoons.  
Using static light scattering detection (Figure 3 B), the main peak observed by UV detection at approx. 
5.6 minutes was confirmed but in addition the small leading peak at approx. 5.0 minutes was more 
pronounced. OL showed three peaks, the retention time of two of them was comparable to carbonate-
degummed samples (peaks at 5.0 and 5.6 minutes). In addition, a new peak was observed at 5.3 minutes 
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(potentially corresponding to the shoulder observed using UV detection). Virtually no static light 
scattering signals were obtained in the case of T120, T180 and IL.  
 
Figure 3. Chromatography of cocoons, C5, C30, C60, C120, OL, T120, T180 and IL (traces from bottom to top in each panel). 
Size exclusion chromatography with (A) UV detection at 215 nm and (B) light scattering detection at 90°. (C) Weak anion 
exchange chromatography with UV detection at 215 nm. 
Weak anion exchange chromatography of cocoon and sodium carbonate treated samples revealed a main 
peak at approx. 9.1 minutes with side peak (less acidic variants) at approx. 8.4 minutes (Figure 3 C). 
With increasing degumming time with sodium carbonate, the main peak area was reduced and new 
variant peaks at approx. 8.6, 8.7 and 8.9 minutes appeared and became more prominent. OL showed a 
similar chromatogram as the cocoon sample with slightly more pronounced variant peaks at 8.4 minutes. 
Chromatograms of T120 and T180 were comparable to C120 with even more pronounced variants 
showing shorter retention times. Finally, IL only showed the variant peak at approx. 8.4 minutes. 
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3.5. Tensile testing 
In Figure 4 the maximum rupture forces and yield points are displayed. Native, untreated fibers had the 
highest rupture force (~ 150 mN) and yield point (~ 60 mN), whereas sodium carbonate treatment 
resulted in significant reduction of both rupture force and yield point with increasing degumming time. 
No significant differences were observed between C60, C120, OL and IL. However, trypsin treatment 
resulted in further significant reduction of mechanical properties, especially comparing C120 with T180. 
Figure 4. Tensile testing of native silk and differently degummed samples: rupture force (black bars) and yield point (grey 
bars).  
3.6. Refractive index 
Within the margin of error of the measurements, no major variation of refractive index with degumming 
method and -duration were observed, neither before nor after methanol treatment to induce beta sheet 
formation (Figure 5). Comparing the results before and after treatment with methanol, no significant 
differences were observed between the two groups either. 
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Figure 5. Refractive indices of native silk, sericin and differently degummed samples before (black bars) and after (grey bars) 
treatment with methanol. 
4. Discussion 
The degumming process, i.e. the removal of sericin from virgin silk, is one of the most critical process 
steps during preparation of regenerated SF, which is increasingly used as a biomaterial for tissue 
engineering, implantable devices, disease models and for drug delivery systems [166]. 
Depending on degumming process conditions, various material properties such as tensile strength, 
molecular weight distribution and micelle formation of SF are affected, ultimately affecting 
performance in biomedical applications such as tissue engineering and drug delivery [16, 156, 164]. 
Furthermore, efficient degumming is crucial with regards to the biocompatibility and immunogenicity 
of SF [15]. Therefore, it is necessary to completely remove sericin, while preserving or controlling SF 
integrity. 
Numerous different processes and conditions have been published for silk fibroin extraction from virgin 
silk, the most common of these processes uses boiling sodium carbonate solution for degumming. 
Traditionally, silk textiles have been treated after weaving with alkali-free olive oil soap (Marseilles 
soap) at 90-98°C for several hours to remove sericin and resulting in reduced brittleness, improved 
handling and characteristic luster of silk textiles [167]. Common alternative degumming processes, 
especially in the context of SF extraction for biomedical applications include enzymatic degradation of 
sericin and, more recently, degumming using ionic liquids [159, 160]. 
Degumming using sodium carbonate solution efficiently hydrolyzed and removed sericin after 
30 minutes as evidenced by evaluation of degumming efficiency based on mass loss (Figure 1 K) and 
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amino acid analysis (Figure 2 D). Extending the process duration beyond 30 minutes did not 
significantly improve degumming efficiency based on either analysis. Published analysis of degumming 
efficiency showed variable results ranging from complete degumming after 5 minutes at 100 °C [15] to 
complete degumming after 40 minutes at 80°C [168], presumably due to variable process conditions 
such as temperature, agitation and silk concentration. Increasing degumming time using sodium 
carbonate on the other hand substantially affected SF integrity. In agreement with previous reports, 
average molecular weight of SF was reduced, and molecular weight distribution increased with 
increasing degumming time (Figure 3 A) [15, 156, 164, 169, 170]. Interestingly, incubation in sodium 
carbonate also resulted in a shift towards less acidic charge variants with increasing degumming time 
(Figure 3 C), suggesting predominant degradation of the light subunit and/or C-terminal region of the 
heavy chain of SF [171]. This conclusion corresponds with the previous finding that beta-sheet content 
of SF is not significantly affected by degumming time [15, 156]. Tensile testing revealed reduction of 
both rupture force and yield point with increasing degumming time. The elastic behavior of silk was 
related to the amorphous phase as well as beta-sheet crystals [172], while rupture force is mainly 
governed by failure of crystalline units [173]. Therefore, it may be hypothesized that degumming in 
addition to degradation of amorphous regions also reduced crystallite integrity resulting in the reduction 
of both yield point and rupture force [16]. Finally, changes in amino acid composition of proteins may 
result in small but significant differences of refractive indices [174]. However, refractive indices showed 
no significant changes in response to increasing degumming time (Figure 4 B), in line with recently 
published results [175] and potentially due to the fact that the contribution of repetitive elements of SF 
heavy chain dominate refractive index. This finding contributes to the conclusion that degradation 
primarily affected non-repetitive regions of SF.  
Oleate degumming was significantly less efficient than other methods and resulted in incomplete 
removal of sericin with degumming efficiency in the range of 44 to 63% (Figures 1 K and 2 D) with 
remnants of sericin coating visible in micrographs (Figure 1 F). In contrast, mass losses of approx. 22 
to 24 % were reported for degumming using Marseille’s soap at 5 g l-1 or 25 % of weight of the fabric 
at 93 or 95 °C and 90 minutes [176, 177], which would be comparable to degumming efficiency 
achieved for C5 in the present study. While SEC and anion exchange chromatography revealed no major 
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degradation and despite incomplete degumming, oleate treated sample showed significantly reduced 
yield point as well as rupture force. Degumming with Marseille’s soap was reported to similarly result 
in pronounced strength loss, even at still incomplete degumming [176]. 
Numerous alternative degumming processes applying various enzymes have been published [176-178]. 
We herein focused on trypsin, due to its wide availability and its reported high degumming efficiency 
[159]. However, in the present study, only moderately efficient degumming of 75 % and 72 % after 
incubation for 120 minutes and of 72 % and 103 % after incubation for 180 minutes was achieved based 
on mass loss and amino acid composition, respectively, which is in good agreement with previous 
findings in another study [179]. Additionally, degumming using trypsin resulted in pronounced SF 
degradation observed in scanning electron micrographs, SEC as well as anion exchange 
chromatography. Tensile testing similarly showed the lowest rupture forces and low yield points after 
degumming with trypsin. Based on these results it is concluded that trypsin under the conditions chosen 
not only degrades sericin but also fibroin, resulting in formation of protein fragments and limiting its 
suitability for degumming of silk for biomedical applications. This result may not be surprising in view 
of numerous studies, which successfully used trypsin for silk fibroin digestion [180, 181]. 
Degumming with ILs may represent another promising degumming approach due to their specific 
properties, e.g. tunability, versatility and low melting point (below 100 °C). IL consist of an inorganic 
ion and an organic, bulky counterion carrying a delocalized charge, which prevents the formation of a 
stable crystal lattice. Long alkyl chains of the organic cation, e.g. 1-butyl-3-methylimidazolium (Bmim), 
are able to interact with the protein, leading to participation or competition of the solvent with intra- and 
intermolecular protein interactions and therefore, to dissolution [182]. In the present study treatment 
with [Bmim]Br resulted in similar degumming efficiency to C5, both by mass loss and amino acid 
analysis (Figure 1 K and 2 D), while SEC showed no major degradation of SF (Figure 3 A). However, 
micrographs (Figure 1 I) showed remnants of sericin on the fiber surface and tensile testing revealed 
substantially reduced rupture force and yield point. Reports in the literature on the effects of ILs on silk 
are controversial. Treatment with [Bmim]OAc resulted in visually complete dissolution of silk fibers 
within 4 minutes at 120 °C [183] while it was reported in another study that only 0.7 % of silk fibroin 
was soluble in [Bmim]Br [160]. Differences in water content of ILs may significantly change the 
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dissolution properties and therefore result in different dissolution characteristics. Furthermore, silk 
fibers were subjected to degumming prior to incubation in ILs in one of the studies, potentially resulting 
in improved SF dissolution due to partial degradation induced by prior degumming. 
5. Conclusion  
Degumming of SF using sodium carbonate not only results in fast sericin removal after 30 minutes but 
also affects SF average molecular weight, molecular weight distribution, isoelectric point and 
mechanical properties. All these properties significantly influence the performance in various 
biomedical applications and may be employed for tuning of SF material characteristics for specific 
applications. As an example, drug release from SF matrices was shown to depend on SF isoelectric 
point, resulting in more sustained release of positively charged propranolol hydrochloride compared to 
negatively charged salicylic acid [184]. Similarly, SF average molecular weight was shown to affect 
drug release kinetics [156].  
Degumming with sodium oleate and trypsin was only moderately efficient but resulted in significant SF 
degradation and/or substantially reduced yield point and rupture strength. On the contrary, degumming 
with IL was quite efficient but requires further optimization to improve tensile properties of SF after 
degumming. 
In summary, degumming using sodium carbonate solution for 30 minutes appears the best degumming 
process among the studied alternatives allowing to retain SF integrity and achieve complete sericin 
removal. 
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Supporting Information 
Figure S1. Scanning electron micrographs of native and degummed fiber samples. (A) native silk fiber, (B) C5, 
(C) C30, (D) C60, (E) C120, (F) OL, (G) T120, (H) T180 and (I) IL. Bar in (A) represents 20 µm and applies to 
all micrographs.  
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Macromolecular Drugs 
 
 
 
 
The experimental part, data analysis and writing of the manuscript were my contribution. The 
manuscript was finalized by Prof. Dr. Oliver Germershaus. 
 
 
– Kira Nultsch – 
 
 
Published in: European Journal of Pharmaceutical Sciences, June 2017 
  
Silk Fibroin Degumming affects Scaffold Structure and Release of Macromolecular Drugs 
  
74 
 
Silk Fibroin Degumming Affects Scaffold Structure and Release 
of Macromolecular Drugs 
 
Kira Nultsch †,¥, Oliver Germershaus *,¥ 
 
† Institute of Pharma Technology, University of Applied Sciences, Gründenstrasse 40, 4132 
Muttenz, Switzerland 
¥ Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 
Basel, Switzerland 
 
 
 
 
 
 
 
 
 
 
 
 
* Corresponding author: 
E-mail address: oliver.germershaus@fhnw.ch (Oliver Germershaus)  
Silk Fibroin Degumming affects Scaffold Structure and Release of Macromolecular Drugs 
  
75 
 
Abstract 
Silk fibroin (SF) is a natural polymer with tremendous potential as a matrix for drug delivery systems 
as well as for tissue engineering. Silk sericin (SS) removal (degumming) is a critical step during SF 
purification, potentially affecting SF integrity and resulting in structural changes such as partial 
hydrolysis and inhibition of micelle formation. In addition to SF composition itself, the molecular 
weight and charge of encapsulated drugs may significantly affect drug release from SF matrices. The 
effect of these parameters on drug release was investigated by varying SF degumming time and charge 
of the model compound encapsulated in SF films. With increasing degumming time, average SF 
molecular weight decreased, molecular weight distribution became broader and formation of SF 
micelles was impaired. However, β-sheet content was not affected by degumming time, suggesting that 
degradation occurred mainly in hydrophilic domains of SF. The release of differently charged dextran 
derivatives, used as macromolecular model drugs, was significantly affected by SF degumming. Release 
of neutral dextran increased with increasing degumming time. In contrast, negatively charged dextran 
showed an inverse effect potentially due to reduced SF charge density with increased degumming time. 
Interestingly, positively charged dextran were shown to partly form polyelectrolyte complexes with SF 
by isothermal titration calorimetry but also exhibited phase separation during film drying resulting in 
fast burst release. These results demonstrate that both, SF preparation as well as drug charge 
significantly affect drug release from SF matrices. 
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1. Introduction 
Silk obtained from cocoons of the domesticated silk worm Bombyx mori was the most common suture 
material since the early 20th century but was largely replaced after the advent of synthetic sutures [185]. 
However, silk was in recent years rediscovered as a natural material for various biomedical applications 
[110]. Silk was applied in numerous drug delivery systems due to its biocompatibility and 
biodegradability [28] and was identified as a promising biopolymer for regenerative medicine [186] and 
the stabilization of biologicals [6].  Preparation of silk-based materials can be performed under very 
mild conditions, i.e. in an entirely aqueous environment and applying no or very low shear force [5, 
187]. 
Silk fibers (bave) consist of two individual silk fibroin (SF) filaments (brins) that are coated with the 
glue-like protein silk sericin (SS). SF comprises a light chain (~25 kDa) and a heavy chain (~350 kDa) 
which are connected by a single disulfide bond. The heavy chain of SF is characterized by repeating 
sequences of GAGAGS, GAGAGY and GAGAGVGY, resulting in formation of antiparallel β-sheets 
and being ultimately responsible for crystalline regions in SF [188]. SF has an approximately isoelectric 
point (IEP) of 4.6 [62], leading to an overall negative charge at physiological pH. 
The presence of SS was associated with lack of biocompatibility and hypersensitivity to silk and hence, 
SS must be efficiently removed in a so called degumming process [14]. This purification process is 
frequently carried out by alkali treatment at elevated temperature, hydrolyzing the amid bonds of sericin. 
However, the degumming process step is assumed to affect the SF integrity. Commonly, 0.02 M sodium 
carbonate is used for degumming [189] whereby higher concentrations and elevated pH values were 
found to increasingly result in SF degradation [190, 191]. Other degumming agents were studied, such 
as formic acid [192], citric acid [157], urea [16], boric acid [16] and different enzymes [17, 178]. Apart 
from type of degumming agent, concentration and pH value, degumming time is a potential major factor 
affecting SF integrity [15, 193]. 
Even though the impact of degumming time on physicochemical properties of silk has been investigated 
in the past, little research has been conducted regarding a) the impact of the degumming time on SF-
based drug delivery system performance and b) how the properties of encapsulated, macromolecular 
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compounds affect the release pattern. Hines et al. investigated the influence of the molecular weight of 
fluorescein labelled dextran on the release pattern as well as the release of negatively charged small 
molecules (dyes) [194, 195].  
Pritchard et al. looked into the effects of the degumming on the SF material and in consequence, the 
influence of the material properties on small molecule drug delivery [164]. However, no studies 
regarding the release of high molecular weight compounds and the effect of differently charged 
compounds have been performed to date. Dextrans are suitable model compounds to study drug delivery 
matrices due to their defined molecular weight and straightforward modification with different residues 
[196]. Dextran derivatives (Figure 1) with similar average molecular weight of 10 kDa and the same 
backbone, but differently charged residues, were chosen to investigate the influence of drug charge on 
release. To assess whether the degumming time and charge of the encapsulated, macromolecular 
compound influence the release pattern, we investigated the release of neutral, positively and negatively 
charged dextran from films, prepared from SF extracted from silk cocoons using increasing degumming 
time. 
 
  
Figure 1. Structural formula of the differently charged dextran derivatives. 
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2. Materials and Methods 
2.1 Materials  
Cocoons of the silkworm (Bombyx mori) were supplied by Wollspinnerei Vetsch (Pragg-Jenaz, 
Switzerland) and Swiss Silk – Vereinigung Schweizer Seidenproduzenten (Hinterkappelen, 
Switzerland). Fluorescein isothiocyanate-dextran (FITC-dextran) 10 kDa, fluorescein isothiocyanate-2-
(diethylamino) ethyl-dextran (FITC-DEAE-dextran) 10 kDa and fluorescein isothiocyanate-dextran 
sulfate (FITC-dextran sulfate) 10 kDa were purchased from TdB Consultancy AB (Uppsala, Sweden). 
Bio-Safe™ Coomassie Stain G-250 was supplied by Bio-Rad Laboratories (Cressier, Switzerland). Cell 
culture plates (6-well-plates) were obtained from Vaudaux-Eppendorf AG (Basel, Switzerland). All 
other chemicals were purchased from Sigma Aldrich (Buchs, Switzerland).  
2.2 Methods 
Gel Electrophoresis. Molecular weight distribution was investigated by sodium dodecyl sulfate 
poly(acrylamide) gel electrophoresis (SDS PAGE) according to the protocol of Laemmli under reducing 
conditions [197]. Briefly, for each sample 20 µg dialyzed SF per band was loaded on a 12% gel and run 
for 90 minutes. The samples were stained with Bio-Safe™ Coomassie for 1 h and then rinsed with water 
for 30 min. 
Size-Exclusion-Chromatography. The chromatographic systems consisted of a quaternary pump, auto 
sampler, column oven, diode array detector (DAD) and a static and dynamic light scattering detector 
(SLS and DLS) (Agilent 1260 Infinity, Agilent Technologies, Santa Clara, CA, USA). The separation 
was performed on an Agilent Bio Sec-3 column (3 µm, 300 Å, 4.6 x 300 mm, Agilent Technologies, 
Santa Clara, CA, USA) with 0.1 M sodium chloride as mobile phase and flow rate of 0.3 mL/min at 25 
°C. The dialyzed SF solution was diluted with the mobile phase to 0.1% solution. 
Fourier Transform Infrared Spectroscopy (FT-IR). To investigate the differences between the 
degumming times, ATR FT-IR spectroscopy using an Agilent Cary 620/670 (Agilent Technologies, 
Santa Clara, CA, USA) was performed. The blank SF films were either left untreated or treated with 
methanol (preparation as described further below) and after drying, measured in a range of 400 cm-1 to 
4000 cm-1 in 4 cm-1 resolution. The spectra were baseline corrected and β-sheet content of the SF films 
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was calculated by Fourier-self deconvolution using Omnic™ Spectra Software (Thermo Fisher, 
Waltham, MA, USA). Amide I (1600 – 1700 cm-1) was chosen for the calculation since the band is 
characteristic for β-sheets. 
SF Film Preparation. SF solution (6% w/w) was mixed with either FITC-dextran, FITC-DEAE-dextran 
or FITC-dextran sulfate (aiming a 15 mg/mL solution) and subsequently, 2.5 mL were dried in 6-well-
plates overnight, resulting in a 25% (w/w) loading [194]. After drying, the films were cut into 
(commensurate) samples of the same size with a hole punch and transferred into glass vials (6 mL). 
Triplicates of each film type (DEAE-D, D and DS) were prepared. The films were treated with 300 µl 
of methanol to induce β-sheets and dried in a fume hood overnight. 
Release Studies. For the in vitro release studies the films were placed in fresh 6 mL glass vials with 2.5 
mL phosphate buffered saline (PBS) and incubated in the dark at 37°C and 30 rpm in an orbital incubator 
shaker (IKA®-Werke, Staufen, Germany). Sink conditions were maintained throughout the release 
studies. After 150 h incubation, the films were collected and dissolved in 2.5 mL Ajiwasa’s reagent to 
determine the unreleased amount of the model compounds. The amount of the released compounds was 
measured by UV/Vis spectroscopy (VWR UV 6300PC, VWR, Dietikon, Switzerland) at 494 nm for 
each time point. To compare the drug release differently charged dextran derivatives, the mean 
dissolution time (MDT) was calculated (Equation 1), where i is the sample number, n is the dissolution 
sample times, Mi is the amount of drug released between t and (t-1), t is the midpoint between t and (t-
1). Statistical significance was calculated by using student’s t-test to compare two groups with a 
significance level of p = 0.05. 
𝑀𝐷𝑇 =  
∑ 𝑡∆𝑀𝑖
𝑛
𝑖=1
∑ ∆𝑀𝑖
𝑛
𝑖=1
     Equation 1  
Table 1. Overview of the varying treatments of the SF films: different degumming times and differently loaded SF films. 
Degumming time / 
min 
Blank films 
Films loaded with FITC-
DEAE-dextran 
Films loaded with 
FITC-dextran 
Films loaded with 
FITC-dextran sulfate 
30 SF 30 DEAE-D 30 D 30 DS 30 
60 SF 60 DEAE-D 60 D 60 DS 60 
120 SF 120 DEAE-D 120 D 120 DS 120 
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Scanning Electron Microscope (SEM). Cross sections of the SF films were sputter coated and 
characterized by SEM (Hitachi TM3030 plus, Hitachi, Krefeld, Germany).  
Confocal Laser Scanning Microscope (CLSM). SF films loaded with FITC-DEAE-dextran, FITC-
dextran or FITC-dextran sulfate were imaged by CLSM (Olympus FV1000, Olympus, Center Valley, 
PA, USA). The CLSM micrographs were recorded using an objective with 10x magnification (NA 0.30) 
and an excitation laser wavelength of 488 nm, a pinhole size of 80 µm, resulting in an optical slice 
thickness of 6.51µm. Emission was detected using a band-pass filter (500-600 nm). 
FT-IR Imaging Analysis. The differently loaded SF films were measured with an FT-IR microscope 
equipped with an ATR germanium crystal (Agilent Cary 620 FT-IR microscope, Agilent Technologies, 
Santa Clara, CA, USA) to investigate the distribution of the model compounds in the SF films. The 
images were collected using the following parameters: resolution 4 cm-1, scan from 4000 to 400 cm-1 
and 64 images per step. Mapping of the SF films was performed using 1520 cm-1 as SF specific 
wavenumber, while dextrans were mapped at ~1000 cm-1. The colors respectively the 
concentration/absorption are not comparable in between the differently loaded films. 
Isothermal Titration Calorimetry (ITC). ITC measurements were performed on a nano ITC (TA 
instruments, New Castle, DE, USA). A 1.5 mM FITC-DEAE-dextran solution was titrated into 30 µM 
SF solution to measure the enthalpy of the reaction. The experiment was conducted at 37°C and the 
solution was stirred at 300 rpm. 20 injections with each 2 µL and 300 s spacing between the injections 
were carried out. 
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3. Results 
Figure 2A shows SDS PAGE analysis of SF after degumming for 30, 60 and 120 minutes (SF 30, SF 
60, SF 120). In general, longer degumming times led to a broader molecular weight distribution. After 
30 minutes the molecular weight was distributed over a range of approximately 75 to 360 kDa whereas 
SF 120 resulted in a broad smear and a shift of the protein distribution to predominantly smaller 
molecular weights (approximately 10 to 75 kDa).  After 30 minutes degumming time, SF light chain 
was still detectable at approximately 25 kDa but was barely visible at 60 minutes degumming and 
entirely degraded at 120 minutes. These results were confirmed by SEC analysis. With increasing 
degumming time, main peaks as detected by UV absorption (Figure 2B) shifted to longer retention time 
due to increasing protein degradation. Furthermore, a leading peak at 6.3 minutes was observed, whose 
height decreased with increasing degumming time. Static light scattering detection (Figure 2C) showed 
Figure 2.  Influence of the degumming time on the molecular weight distribution. A) SDS PAGE. A and E indicate the marker. SF 30 
(B), SF 60 (C) and SF 120 (D). The graphs B) and C) depict the result of the size exclusion chromatography, where B) shows the UV 
detection and C) the light scattering. 
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a peak at 6.4 minutes with tailing up to a retention time of approximately 13 minutes. As with UV 
detection, peak height was decreased with SF 60 and almost disappeared in the case of SF 120.  
Figure 3A presents the FT-IR spectrum of SF 30, before and after methanol treatment to induce β-sheet 
formation. Untreated SF 30 showed bands for amide I (C=O stretching) at 1635 cm-1, amide II 
(secondary N-H bending) at 1515 cm-1 and amide III (C-N stretching) at 1232 cm-1. Methanol treatment 
induced a shift of the amide I band to 1619 cm-1 (amide II 1513 cm-1, amide III 1230 cm-1), indicating 
β-sheet formation [198, 199]. No shift in the amide III band suggested that besides β-sheets there were 
also remaining random coil structures in the protein. Untreated SF120 showed bands at 1638 cm-1 (amide 
I), 1514 cm-1 (amide II) and 1235 cm-1 (Figure 3B), similar to untreated SF 30. Methanol treated SF 120 
showed bands at 1621 cm-1 (amide I), 1517 cm-1 (amide II) and 1235 cm-1 (amide III), suggesting β-
sheet formation. The β-sheet content of methanol treated SF films ranged between 0.39 and 0.47 and no 
significant differences between SF30, SF60 and SF120 were observed. 
 
Figure 3. FT-IR spectra of SF after different degumming times. A) SF 30, untreated (solid line) and ethanol treated (dotted line). 
B) SF 120, before (solid line) and after methanol treatment (dotted line). 
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No significant differences between the release profiles from SF films were found for FITC-DEAE-
dextran (Figure 4A). The MDT of FITC-DEAE-dextran loaded films was also not significantly different 
between the different degumming times (DEAE-D 30: 5.732 h ± 1.891 h, DEAE-D 60: 4.470 h ± 4.356 
h, DEAE-D 120: 6.678 h ± 3.640 h). The release profiles obtained with FITC-dextran showed increasing 
burst release with increasing degumming time (Figure 4B). Longer degumming times overall led to 
reduced MDT, whereby the MDT of D 30 compared to D 120 and D 60 compared to D 120 differed 
significantly (D 30: 40.530 h ± 7.760 h, D 60: 36.913 h ± 5.126 h, D 120: 17.755 h ± 3.553 h).  
For films loaded with negatively charged FITC-dextran sulfate the order of the release was inversed 
compared to FITC-dextran (Figure 4C). Shorter degumming times resulted in a more pronounced burst 
release compared to longer degumming times. The MDT increased with longer degumming time, 
Figure 4. Cumulative release profiles from SF films applying degumming time of 30, 60, and 120 minutes and loaded with A) FITC-
DEAE-dextran, B) FITC-dextran, and C) FITC-dextran sulfate. 
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whereby the release rate of DS 30 compared to DS 120 differed significantly (DS 30: 10.545 h ± 2.977 
h, DS: 22.115 h ± 7.271 h, DS 120: 29.278 h ± 1.566 h). 
Cross-sections of the blank and loaded films were imaged using SEM (Figure 5). The porosity of blank 
films appeared to decrease with increasing degumming time (Figure 5A SF30, B SF 60, C SF 120). 
Films loaded with FITC-DEAE-dextran were more compact and less porous than all other films and 
instead had numerous large holes on the surface and within the films.  
Films loaded with FITC-dextran and FITC-dextran sulfate appeared less porous than the blank films, 
with small pores visible on the surface and within the films.  
Figure 5. Cross-sections of SF ﬁlms after diﬀerent degumming times. A) 30min. B) 60 min. C) 120 min. SF 30, SF 60 and SF 120 
depict blank ﬁlms. SF ﬁlms loaded with I) FITC-DEAEdextran, II) FITC-dextran and III) FITC-dextran sulfate before release studies, 
whereas SF ﬁlms loaded with AR I)FITC-DEAE-dextran, AR II) FITC-dextrana nd AR III) FITC-dextran sulfate after release are 
showed. Scale bar in SF30 represents 50 μm and is valid for all pictures. 
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After drug release, with longer degumming times the films loaded with FITC-dextran appeared more 
compact (Figure 5A, B, C AR II), whereby FITC-dextran sulfate loaded films appeared more porous 
than before the release and more pores were visible on the surface (Figure 5A, B, C AR III). Films 
loaded with FITC-DEAE-dextran appeared still solid after release, showing no major differences 
compared to the appearance before drug release. 
CLSM micrographs showed that FITC-dextran and FITC-dextran sulfate were distributed evenly in the 
films (Figure 6). FITC-DEAE-dextran accumulated on the film surface (red arrows). After release, the 
accumulation of FITC-DEAE-dextran on the film surface disappeared whereas the FITC-dextran and 
FITC-dextran sulfate was still equally distributed. 
Figure 6. CLSM pictures of SF 60 loaded with (I) FITC-DEAE-dextran, (II) FITC-dextran and (II) FITC-dextran sulfate, 
before release (first row) and after release studies (AR). Scale bar in I indicates 250 µm and is valid for all pictures. 
FT-IR mapping was used to study the distribution of SF and dextrans on the film surface after film 
preparation (Figure 7). While SF and FITC-dextran or FITC-dextran sulfate were evenly distributed, 
SF films loaded with FITC-DEAE-dextran showed phase separation and spot-like accumulation of 
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dextran on the film surface (Figure 7 B I), confirmed by the absence of SF (Figure 7 A I) in these spots 
(red arrows). 
Figure 7. FT-IR mapping of SF 60 loaded with (1) FITC-DEAE-dextran, (2) FITC-dextran and (3) FITC-dextran sulfate, 
mapping using wavenumbers specific for (A) SF and (B) dextrans. Scale bar in A1 represents 10 µm, magnification of all 
micrographs is equal. 
The interaction between FITC-DEAE-dextran and SF were measured by ITC (Figure 8). A maximum 
heat liberation was observed at a molar ratio of 6:1 FITC-DEAE-dextran:SF. With a higher molar ratio 
than 6 a regression of the liberated heat was observed.  
Figure 8. Interaction of FITC-DEAE-dextran and SF 60 in PBS. 
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4. Discussion 
Degumming is a crucial process step in the purification of SF where sericin is removed by treating SF 
with alkaline solution at elevated temperature, resulting in hydrolytic cleavage of amid bonds. This 
process step is inherently unspecific and therefore threatens SF integrity. The degumming time 
considerably affected molecular weight distribution of SF (Figure 2). Shorter degumming times resulted 
in a narrower distribution of molecular weights, while longer degumming times caused more 
pronounced SF degradation signified by broader molecular weight distribution and a shift towards low 
molecular weight fragments. These observations are well in line with results obtained in previous studies 
[15, 164, 200, 201]. Static light scattering detection employed during SEC revealed the presence of 
structures with very high molecular weight, close to the exclusion limit of the column. These species 
were detectable by UV absorption in the case of silk degummed for 30 minutes but only detectable as a 
small shoulder in the case of 60 or 120 minutes degumming samples. Again, these findings are in line 
with data published by Wray et al. but the presence of additional species in SEC analysis was not further 
discussed in this paper [15]. Being an amphiphile, SF forms micellar structures of approximately 100 to 
200 nm in water, where large hydrophilic N- and C-termini form the hydrophilic shell and large 
hydrophobic blocks with small interspersed hydrophilic blocks form the core of the micelle [2, 62, 202]. 
It is therefore assumed that the very high molecular weight structures eluting close to the exclusion limit 
of the column represent SF micelles. Interestingly, the concentration of these species is reduced with 
increasing degumming time both in the present study (Figure 2B) as well as in the data published by 
Wray et al. [15], assuming that longer degumming times led to higher protein degradation and as a 
result, to aggravated micelle formation.  
Treatment of SF with methanol or water vapor induces β-sheet formation, whereupon methanol 
treatment was shown to be more effective (β-sheet content 0.4 - 0.53 [199]) and resulted in a higher 
surface hydrophobicity [200]. FT-IR spectra (Figure 3) did not show relevant differences between the 
different degumming times nor any relevant changes of β-sheet content (0.39 - 0.47) despite pronounced 
SF degradation as detected by SEC and SDS-PAGE (Figure 2). These findings suggest that the 
crystalline Gly-X domains are less likely to be degraded during degumming, still allowing formation of 
β-sheeted crystalline regions after regeneration and point to region-specific degradation of SF primarily 
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in the amorphous regions as well as N- and C-termini during degumming [15]. Based on this 
interpretation of the data it seems reasonable to hypothesize that regio-specific degradation of 
hydrophilic domains of SF leads to alteration or even inhibition of SF micelle assembly, which would 
explain the reduction of concentration of very high molecular weight structures with increasing 
degumming time as detected by static light scattering. This interpretation could also serve to further 
explain the microstructural differences between films obtained from differently degummed SF as 
observed by SEM in the present study (Figure 5 A SF 30, B SF 60, C SF 120 and by Wray et al. [15]. 
In their study on silk fibroin self-assembly, Lu et al. studied SF, obtained by using short degumming 
time (20 minutes), and showed that SF micelles assemble into fibrils at concentrations above 
approximately 20% (w/w) [202]. Such fibril formation would be inhibited if micelle concentration is 
reduced or no micelles are present at all, resulting in pronounced differences in film microstructure.  
In the next step, the effect of variation of degumming conditions on drug release was investigated using 
neutral and charged 10 kDa dextrans as model drugs. Drug release from silk fibroin film was shown to 
be driven by diffusion and only marginally by matrix degradation due to very slow degradation of SF 
in the release medium [194, 195].  Region-specific degradation of SF was assumed to change the 
molecular as well as microscopic structure of SF films and hence, affect diffusion driven release of 
model compounds. Mean dissolution time of FITC-dextran, representing a virtually uncharged 
compound, was shorter after longer degumming times, meaning a faster release, which is assumed to be 
due to higher diffusivity of FITC-dextran in the SF matrix. Similar results were obtained by Pritchard 
et al. studying diffusion of indigo carmine (466.35 g/mol), rifampicin (822.94 g/mol), reactive-red 120 
(1469.98 g/mol), and azoalbumin (66.4 kDa) through SF films, where the release of all compounds 
increased for methanol treated SF films with increasing degumming time [164]. Furthermore, loading 
of SF films with FITC-dextran changed the microscopic structure of film cross sections compared to 
blank films. However, no pronounced differences of the microscopic structure were observed between 
loaded films prepared using SF obtained using different degumming times in contrast to blank films. 
Interestingly, using negatively charged FITC-dextran sulfate an inversed effect of degumming time on 
drug release was observed compared to neutral FITC-dextran. We interpret this finding as an effect of 
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regional degradation of SF as outlined above affecting mainly the charge bearing N- and C- termini and 
hydrophilic, non-repetitive domains of SF, which contribute to the net negative charge of SF at 
physiological pH [203]. As described above, increasing degumming time results in increased hydrolytic 
degradation of hydrophilic regions of SF, which are also the regions comprising charged amino acids, 
and therefore, potentially reduce net charge of the matrix. Hence, electrostatic repulsion between 
negatively charged dextrans and SF matrix is reduced with increasing degumming time, leading to 
shorter MDT (faster release) of FITC-dextran sulfate. This finding and interpretation correlates well 
with the study of Hines et al., in which loading of SF films with negatively charged dyes lead to 
increased diffusion coefficients, which was attributed to electrostatic repulsion between negatively 
charged dyes and negatively charged SF [195].   
FITC-DEAE-dextran is a polycationic dextran derivate containing three basic groups (pKa1 = 9.5; pKa2 
= 5.7, pKa3 = 14). Therefore, release profile of FITC-DEAE-dextran was expected to be slowest (highest 
MDT) due to attractive electrostatic interactions between positively charged DEAE residues and 
negatively charged domains of SF. Indeed, attractive interaction between FITC-DEAE-dextran and SF 
was confirmed by ITC (Figure 8), showing complex formation in PBS up to a molar ratio of 6:1 FITC-
DEAE-dextran:SF. In contrast, no interaction was observed by ITC between either FITC-dextran or 
FITC-dextran sulfate and SF (data not shown). Similar complex formation between SF and polycationic 
compounds was observed by ITC in a previous study [204]. In contrast to our expectations, we found 
that the MDT of FITC-DEAE-dextran from SF was shorter than uncharged and negatively charged 
dextran due to supersaturation of binding sites between FITC-DEAE-dextran and SF. The MDT was 
not significantly affected by degumming time. Similar release profiles were obtained with an alternative 
polycationic dextran derivative (FITC-Q-dextran, see supporting information). Furthermore, in contrast 
to SF films loaded with FITC-dextran or FITC-dextran sulfate, films loaded with FITC-DEAE-dextran 
appeared compact and non-porous by SEM. Confocal microscopy and FT-IR-imaging further showed 
that phase separation occurred in the case of FITC-DEAE-dextran loaded films, but FITC-dextran and 
FITC-dextran sulfate appeared to be homogenously distributed within the SF matrix. These results 
suggest that FITC-DEAE-dextran forms polyelectrolyte complexes with SF and/or charged SF 
fragments, inhibiting micelle formation and resulting in compact, non-porous films independent of 
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degumming time. Furthermore, only a fraction of FITC-DEAE-dextran may form polyelectrolyte 
complexes with SF as shown by ITC, resulting in exclusion of the remaining FITC-DEAE-dextran and 
hence, phase separation as observed by FT-IR-imaging and CLSM. Finally, phase-separated FITC-
DEAE-dextran is rapidly released (burst release) while complexed DEAE-dextran is not released (steady 
release) within the timeframe of the release study. These results are in line with the findings of He et al. 
showing that only a part of carboxymethyl chitosan was able to interact with silk fibroin, higher 
concentrations led to phase separation [205]. Therefore, the interaction between SF and the model 
compound plays a key role for controlled release. 
5. Conclusions 
The degumming time is an important parameter to influence drug release from SF-based drug delivery 
systems. Degumming time not only affected molecular weight distribution of SF but also charge 
distribution of the matrix as well as micelle formation. Release of differently charged dextrans from SF-
based films was significantly affected by these changes of SF characteristics. While release of neutral 
dextran was mainly related to SF molecular weight-dependent diffusivity in the matrix, the release of 
negatively charged dextran appeared to depend on matrix charge. Finally, positively charged dextrans 
formed polyelectrolyte complexes with SF, resulting in significantly changed film morphology, phase 
separation and rapid release. 
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Supporting Information 
Release studies of FITC-Q-dextran were depicted to compare two different, positively charged dextran 
derivatives, since FITC-DEAE-dextran made an exception regarding the release studies. 
Figure S1. Release studies of SF with different degumming times, loaded with FITC-Q-dextran. 
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Abstract 
Silk fibroin (SF) extracted from the silkworm Bombyx mori was processed into films and the use as 
potential drug delivery system was studied. In this study, we demonstrate a new way to control the 
release of macromolecular compounds by chemical modification. For this, the tyrosine residues of SF 
were coupled with a diazonium salt in a first step and the efficiency of the reaction was studied with 
UV/Vis. Films were loaded with FITC-dextran derivatives of different molecular weights (10, 20 and 
70 kDa) and charges and the release was investigated by comparison of virgin films (vSF) with different 
degrees of modification (0.1 (cSF_0.1) and 1.0 (cSF_1.0) equivalents added). Therefore, the films were 
crosslinked with a poly (ethylene glycol) crosslinker via click chemistry (copper (I) catalyzed alkyne 
azide cycloaddition CuAAC). The latter provides a powerful tool to tailor the characteristics of 
biomacromolcules. By introduction of the hydrophilic crosslinker, film properties could be tailored, 
resulting in a decreased contact angle and higher degree of film swelling. Mean dissolution time (MDT) 
could be significantly increased, allowing a more sustained release. In conclusion, these findings provide 
a promising tool for controlling the release from silk-based drug delivery systems. 
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1. Introduction 
The use of natural and semi-synthetic polymers for tissue engineering and drug delivery has received 
increasing interest in recent years [110]. They have to meet several requirements, for example 
biocompatibility, biodegradability into non-toxic products, economical production and possible 
fabrication for a broad range of applications (films, foams, particles and gels) [6, 206]. Silk fibroin (SF) 
derived from silk of the silk worm (Bombyx mori) is a suitable candidate for a wide variety of 
applications ranging from textiles to biomedical use [5]. Silk fibroin comprises excellent properties for 
drug delivery systems, e.g. mechanical stability, slow degradation, biocompatibility and processability 
in aqueous medium [6]. 
In general, functionalization of natural polymers can widen the range of “smart” and “interactive” 
materials [207]. The most common way to functionalize proteins, especially SF, is the activation of 
carboxylic groups with a carbodiimide (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide EDC) and the 
coupling via N-hydroxysuccinimide (NHS) [208]. However, only 0.5 mol % (corresponds to 25 residues 
per fibroin molecule) aspartic acid, 0.6 mol % (corresponds to 30 residues per fibroin molecule) glutamic 
acid and 0.3 mol % (corresponds to 12 residues per molecule) lysine are exhibited within SF, making 
only 1.5 mol % accessible to be modified via EDC/NHS chemistry [208]. Tyrosine residues represent 
approximately 5 mol % (corresponds to 125 residues per SF molecule) and are homogeneously 
distributed within SF, therefore modification of tyrosine residues is more efficient and achieves higher 
degrees of modification [208]. Different strategies have been investigated, including cyanuric chloride-
activated coupling [209], enzyme catalyzed reactions [207, 210-212] and sulfatation of tyrosine residues 
with chlorosulfonic acid [213, 214]. However, these reactions are limited in yield and/or the specificity. 
To overcome these drawbacks copper (I)-catalyzed azide alkyne cycloaddition (CuAAC, click 
chemistry) was introduced to modify tyrosine residues of silk fibroin [215-217]. This reaction is 
conducted in two steps: firstly, the phenolic group of the tyrosine residue is activated by diazonium 
coupling and secondly, the formed azo derivative is coupled with the alkyne group.  
Murphy et al. studied the diazonium coupling with regard to the change of overall hydrophilicity by the 
introduction of different aniline derivatives and the effect on attachment, growth and differentiation of 
human bone marrow-derived mesenchymal [215]. After 7 days of incubation, all azo SF derivatives 
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showed the same cell growth, whereas after 12 days of incubation SF decorated with negatively charged 
aniline derivatives exhibited the highest proliferation. On the other hand, drug release of dextran 
derivatives with different molecular weight (4, 20 and 40 kDa) was studied from photo-crosslinked 
hydrogels based on inter-penetrating poly (vinyl alcohol) methacrylate/SF network [218]. All hydrogels 
showed an initial burst release due to the release of the surface bound dextran. The release could be 
decreased by increasing the amount of poly (vinyl alcohol) methacrylate. Since SF was not covalently 
bound to the poly (vinyl alcohol) methacrylate matrix, SF was supposed to be released together with the 
dextran derivative and therefore, decreasing SF amount in the matrix resulted in a faster release [212]. 
Due to the slow degradation rate of SF, drug release kinetics is mainly determined by passive diffusion 
[194]. As a result, the release of drugs from SF matrices strongly depends on process conditions and on 
drug properties such as molecular weight and charge [156, 194, 195]. To further control drug delivery, 
either the drug can be covalently bound to the SF matrix or drug diffusion can be controlled by 
crosslinking of the SF matrix. Previous studies showed that covalent attachment of drug to SF matrices 
is a promising approach to increase stability and extend half life [219]. 
In this study, SF was chemically modified to extend its excellent intrinsic properties and enhance its 
performance as drug delivery system. In our previous study, we investigated the influence of SF 
purification on its physicochemical properties and its effect on drug release [156]. To expand the use of 
SF as scaffold for drug delivery, tyrosine residues were crosslinked, mainly on the film surface via click 
chemistry, so that the release of encapsulated drugs can be controlled resulting in a more sustained 
release. Differently charged dextran derivatives and dextran derivatives with different molecular 
weights were used as macromolecular model compounds and the release in relation to the degree of 
modification was studied. As a crosslinker, poly (ethylene glycol) (PEG, 1000 Da) was applied since 
PEG is biocompatible, non-immunogenic, and is frequently used for biomedical applications [220]. In 
this report, we demonstrate a new approach to control drug delivery and, additionally, tailor the 
properties of fibroin, e.g. introduction of hydrophilicity.  
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2. Materials and Methods 
2.1 Materials 
Cocoons of the silkworm (Bombyx mori) were supplied by Wollspinnerei Vetsch (Pragg-Jenaz, 
Switzerland). Fluorescein isothiocyanate-dextran (FITC-dextran) 10 kDa, ﬂuorescein isothiocyanate-2-
(diethylamino) ethyl-dextran (FITC-DEAE-dextran) 10 kDa and ﬂuorescein isothiocyanate-dextran 
sulfate (FITC-dextran sulfate) 10 kDa were purchased from TdB Consultancy AB (Uppsala, Sweden). 
All other chemicals were purchased from Sigma Aldrich (Buchs, Switzerland). 
2.2 Methods 
2.2.1 Silk fibroin purification and film preparation 
Fibroin was degummed as described elsewhere [156]. In brief, the cocoons were cut into small pieces 
and boiled in 0.02 M sodium carbonate solution for 60 minutes at a concentration of 5 g l-1 under constant 
stirring (300 rpm). Afterwards the residual fibers were dried in a fume hood overnight and then dissolved 
in Ajisawa’s reagent (1 mol calcium chloride, 2 mol ethanol, 8 mol water). The solution was filtered 
through a 5 µm syringe filter (Yeti PVDF, HPLC syringe filter, Infochroma AG, Zug, Switzerland) and 
dialyzed against ultrapure water for 48 hours, using a SpectraPor® dialysis tube (SpectraPor® dialysis 
tubes MWCO 6–8 kDa, Spectrum Laboratories, Rancho Dominguez, CA, USA). Dialyzed SF solution 
was concentrated against 10 % poly (ethylene glycol) 35 KDa solution and the mass of a known volume 
of concentrated SF solution was determined gravimetrically and adjusted to a final concentration of 6% 
(w/v). Silk fibroin solution was mixed with FITC-dextran of different molecular weights (10, 20 and 70 
kDa) and charges (positively charged FITC-DEAE-dextran, negatively charged FITC-dextran sulfate) 
to result in loading of 25% (w/w). Subsequently, 2.5 ml of the solution were transferred into one well 
of a 6-well plate and dried overnight at room temperature. After drying, the films were cut into samples 
of 1 cm in diameter with a hole punch and treated with methanol to induce β-sheet formation overnight. 
2.2.2. Modification of tyrosine residues 
Modification of tyrosine residues by diazonium salt formation was performed and monitored by UV/Vis 
spectroscopy as described previously with slight modifications [215]. In brief, 1.25 ml of 0.2 M 4-
azidoaniline (in acetonitrile:water 1:1) was mixed with 625 µl of 1.6 M p-toluenesulfonic acid (aqueous 
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solution) in an ice bath (diazonium salt stock solution). Afterwards, 625 µl of 0.8 M sodium nitrite was 
added, vortexed for 15 seconds, and the mixture was allowed to react for 15 minutes. After extraction 
from cocoons and dialysis (vide supra), SF solution was diluted to a concentration 0.5 % (w/v) and 
incubated with diazonium salt solution, aiming a conversion of 0.1 or 1.0 equivalents of tyrosine 
residues, respectively. The concentration of azo fibroin was calculated using Lambert-Beer law with an 
estimated extinction coefficient of 22000 M-1cm-1 and a peak maximum at λ=329 nm [221]. 
2.2.3 Chemical modification of films via click chemistry 
Tyrosine residues of SF were chemically modified as described in [215, 216] (Scheme 1). In all 
experiments, the films were incubated in 500 µl solution, therefore the diazonium salt stock solution 
was diluted in order to modify different fractions of tyrosine residues, 0.1 and 1.0 equivalents of 
diazonium salt, relative to the total number of 125 tyrosine residues per fibroin molecule. After adding 
the appropriate volume of diazonium salt solution, the reaction was allowed to proceed for 30 minutes 
in an ice bath. In the next step, the modified tyrosine residues were crosslinked with alkyne-PEG (1000 
Da)-alkyne (Creative PEGWorks, Chapel Hill, NC, USA) as described in (Scheme 1) [222]. The 
modified films were washed three times with water to remove residual reagents. Stock solutions of 20 
mM copper sulfate (CuSO4), 50 mM tris (3-hydroxypropyltriazolyl-methyl) amine (THPTA), 100 mM 
sodium ascorbate and alkyne-PEG-alkyne (all in water) were prepared. CuAAC reaction was performed 
using a premixed solution of CuSO4 and THPTA stock solutions (2.5 and 5 µl), 25 µl sodium ascorbate 
stock solution and 457.5 µl alkyne-PEG-alkyne (with the desired concentration to achieve different 
degrees of modification: 6.5 ∙ 10-6 respectively 6.5 ∙ 10-8 mol) and modified fibroin films were incubated 
with the solution for two hours at room temperature. Subsequently, the films were washed three times 
with water to remove residual reagents. Films were designated vSF for virgin, unmodified SF films, 
cSF_0.1 for SF films with 0.1 equivalents of tyrosine modified after crosslinking and cSF_1.0 for SF 
films with 1.0 equivalents of tyrosine modified after crosslinking. 
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Scheme 1. Modification of the tyrosine residues by diazonium coupling and crosslinking of SF via click chemistry. 
2.2.4 Swelling 
SF films without drug (vSF, cSF_0.1 and cSF_1.0) were incubated for 24 hours in water. Afterwards 
non-absorbed surface water on the films was removed with a paper towel, films were weighted, and 
water content was determined by thermogravimetric analysis (Perkin Elmer TGA 4000, Wellesley, MA, 
USA). For TGA measurements, samples were heated to from 30 to 150 °C at a rate of 10 °C min-1 and 
nitrogen flow of 20 ml min-1 and temperature was kept constant until sample weight was constant. Water 
content was determined according to Equation 1. 
𝑚% =  
𝑚𝑏𝑒𝑓𝑜𝑟𝑒 𝑇𝐺𝐴−𝑚𝑎𝑓𝑡𝑒𝑟 𝑇𝐺𝐴
𝑚𝑏𝑒𝑓𝑜𝑟𝑒 𝑇𝐺𝐴
 ∙ 100 %     Equation 1 
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2.2.5 Contact angle measurement 
Contact angle measurements of films without drug (vSF, cSF_0.1 and cSF_1.0) were performed using 
sessile drop method (DSA 100, Krüss GmbH, Hamburg, Germany). Measurements were performed by 
deposition of a drop of deionized water (4 µl) onto the surface of SF films. Evaluation of the contact 
angle was done after 20 seconds, since no change of the droplet shape occurred thereafter. The static 
contact angle was acquired by fitting the symmetric water drop with conic section method (assuming an 
ellipse as drop shape). The contact angle was determined as angle between the baseline and the tangent 
at the conical section of the curve. 
2.2.6 Release studies 
Fibroin films loaded with different dextran derivatives were placed in 6 ml glass vials and incubated 
with phosphate buffered saline (pH 7.4) at 37 °C in an orbital shaker (IKA®Werke, Staufen, Germany) 
at 30 rpm. Release studies were conducted under sink conditions. After 96 hours, fibroin films were 
dissolved in Ajisawa’s reagent to determine the amount of unreleased model compound. Release media 
samples were analyzed with UV/Vis spectroscopy (VWR UV 6300PC, VWR, Dietikon, Switzerland) 
at λ=494 nm. To compare release characteristics of different molecular weights and charges, mean 
dissolution time (MDT) was calculated for each sample (KinetDS v3.0, 
(https://sourceforge.net/projects/kinetds/) according to Equation 2. Herein, i describes the sample 
number, n the dissolution sample times, Mi the amount of drug released between time point t and (t-1) 
and t is the midpoint between t and (t-1).  
𝑀𝐷𝑇 =  
∑ 𝑡∆𝑀𝑖
𝑛
𝑖=1
∑ ∆𝑀𝑖
𝑛
𝑖=1
        Equation 2 
2.2.7 Statistical Analysis 
All measurements were performed in triplicates unless stated otherwise and all results are presented as 
mean ± standard deviation. In order to identify statistically significance, Student’s t-test (release studies) 
or one-way ANOVA with Tukey’s test was performed. Probability values with p ≤ 0.05 were considered 
statistically significant. 
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3. Results 
3.1 Diazonium coupling reaction and degree of modification 
In order to investigate the conversion of tyrosine residues into the azobenzene derivative, different 
equivalents of diazonium salt (0, 0.1 and 1.0 equivalents) were added to a SF solution and analyzed by 
UV/Vis spectroscopy. After nucleophilic substitution reaction the color of the solution changed from 
colorless to yellow-brownish (Figure 1A) and a strong absorption with a peak maximum at λ = 329 nm 
appeared due to the newly formed azobenzene chromophor (π – π*, n – π* transitions; Figure 1B). 
Furthermore, the percentage of modified tyrosine residues was determined by comparison of molar 
concentration of the azobenzene derivative with the theoretical molar concentration of tyrosine residues 
present in SF (assuming 125 tyrosine residues per SF molecule). After addition of 0.1 equivalents, 
approximately 9 % of the tyrosine residues were converted, whereas after addition of 1.0 equivalents 
approximately 86 % of the tyrosine residues were converted. These results indicate that the reaction 
proceeds almost completely (~ 90 %).  
3.2 Swelling 
The ability of SF films to absorb water was measured using TGA. While in the case of vSF water 
absorption was 14.9 ± 1.0 %, statistically significantly higher swelling was observed for crosslinked 
films (21.8 ± 0.2 % for cSF_0.1 and 24.0 ± 1.8 % for cSF_1.0). 
Figure 1. Formation of azobenzene derivative with SF tyrosines. (A) Virgin SF solution, 0.1 and 1.0 equivalents added to the SF 
solution. (B) UV/Vis spectrum of the virgin SF solution (black line), and after addition of 0.1 (dashed line) and 1.0 (dotted line) 
equivalents of diazonium salt. 
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3.3 Contact angle  
The change in SF film surface hydrophilicity was quantified by contact angle measurement. vSF 
exhibited the highest contact angle (75.8 ± 2.0 °), whereas the introduction of the PEG crosslinker led 
to a decrease of the contact angle to 70.5 ± 0.5 ° in the case of cSF_0.1 and 54.3 ± 6.4 ° for cSF_1.0. 
3.4 Drug release 
In general, the release profiles of vSF were characterized by burst release. Crosslinking of 0.1 or 1.0 
tyrosine equivalents resulted in reduction of burst release (Figure 2A), whereby the MDT of vSF 
compared to cSF_0.1 and cSF_1.0 differed significantly (Table 1). FITC-dextran with a molecular 
weight of 20 kDa showed in general a slower release compared to FITC-dextran with a molecular weight 
of 10 kDa. MDT was significantly increased within a higher crosslinking degree (Figure 2B). Results 
obtained with FITC-dextran 70 kDa showed an even lower burst release compared to the other two 
molecular weight dextrans, though MDT was only significantly decreased when comparing vSF to 
cSF_0.1 (Figure 2C). MDT of the positively charged dextran from vSF films was the lowest, equivalent 
to the fastest release and MDT was significantly decreased after crosslinking (Table 1). In line with 
results obtained with neutral dextran, the burst release was significantly decreased after crosslinking, 
confirmed by prolonged MDT (Figure 2D, Table 1). Similar results were obtained with the negatively 
charged FITC-dextran sulfate (Figure 2E). MDT significantly increased when comparing vSF to 
cSF_1.0 and cSF_0.1 to cSF_1.0 (Table 1).  
Table 1. Mean dissolution time of different dextran derivatives from non-crosslinked and crosslinked SF films. 
 
Mean dissolution time / h 
FITC-dextran  
10 kDa 
FITC-dextran  
20 kDa 
FITC-dextran  
70 kDa 
FITC-DEAE-
dextran 10 
kDa 
FITC-dextran 
sulfate 10 kDa 
vSF 10.034 ± 0.658 12.994 ± 1.502 12.290 ± 0.864 5.378 ± 2.016 17.781 ± 1.464 
cSF_0.1 16.079 ± 0.104 16.937 ± 0.239 10.790 ± 0.082 11.053 ± 3.511 17.000 ± 0.159 
cSF_1.0 16.757 ± 0.682 21.099 ± 1.961 11.569 ± 1.504 19.077 ± 4.096 29.260 ± 0.272 
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Figure 2. Cumulative release of (A) FITC-dextran 10 kDa, (B) FITC-dextran 20 kDa, (C) FITC-dextran 70 kDa, (D) FITC-
DEAE-dextran 10 kDa and (E) FITC-dextran sulfate 10 kDa from vSF (black line), cSF_0.1 (dashed line) and cSF_1.0 (dotted 
line). 
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4. Discussion 
A novel approach for controlling the drug release from silk fibroin scaffolds is presented in this study. 
SF comprises only limited options for functionalization due to the low mol percentage of amino acids 
allowing straightforward modification. However, SF contains approx. 5 mol % tyrosine residues, which 
can be efficiently modified by diazonium coupling allowing straightforward introduction of a click 
handle. Reaction conditions are compatible with the fibroin properties, i.e. SF shows good stability at 
basic pH [208, 215]. In addition, the reaction is fast and efficient, requiring 15 minutes for diazonium 
coupling and two hours for the crosslinking by click chemistry.  
Azobenzene derivative formation was found to be efficient, with degrees of conversion of approx. 90 
%. These results are in line with previous studies [215, 216]. When tyrosine residues were modified 
with different aniline derivatives, the highest level of modification were obtained for aniline derivatives 
with electron-withdrawing groups (~ 70 % efficiency) [215]. Hence, modification with azidoaniline can 
provide the necessary specificity compared to other modification options (e.g. EDC/NHS chemistry) 
[216]. On the contrary, only approx. 1.5 mol% of SF amino acids can be modified by EDC/NHS 
chemistry, significantly limiting the degree of modification [208]. Furthermore, instability of SF in the 
presence of EDC/NHS in 2-(N-morpholino) ethanesulfonic acid (MES) buffer due to formation of intra- 
and intermolecular beta-sheet structures was observed [216].  
In the second step, the films were crosslinked with a PEG linker (Scheme 1) to control drug release and 
to tailor SF properties. The incorporation of PEG led to an overall increased hydrophilicity of 
crosslinked SF compared to vSF, which is in agreement with results obtained for similar SF-PEG 
conjugates [209, 215, 220]. The incorporation of cyanuric acid activated PEG 10 kDa led to a decrease 
of the contact angle of up to 33 ° [209], resulting in significantly lower contact angle compared to our 
study due to the higher hydrophilicity of PEG. Similar results were obtained in another study where SF 
was modified with PEG 2 kDa via click chemistry [220]. For this, azido modified SF was reacted with 
acetylene terminal PEG and after SF modification, films were prepared, resulting in contact angles 
between 30 and 44.3 ° (dependent on degree of modification). A possible explanation for differences in 
the contact angle is that methanol treatment to induce β-sheet formation was done after modification 
with PEG [220], leading to different arrangement of β-sheet and therefore, different surface 
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hydrophilicity [220]. The ability to absorb water was significantly higher compared to our results (44 – 
66 % vs. 21 – 24 %). In contrast to this study, we firstly prepared the films, followed by β-sheet 
formation with methanol and then, the films were crosslinked. One hypothesis is that the SF chains are 
less flexible (when crosslinked after β-sheet formation), therefore the penetration of the crosslinking 
reagents into films was aggravated, resulting in modification of SF films mainly on the film surface. 
Since SF is in general a hydrophobic protein [62, 223] and if the core of the SF films are not or less 
crosslinked (with the hydrophilic PEG crosslinker), water penetration into the film matrix will be 
prohibited.  
 
In previous studies, it was found that on the one hand, degumming time during SF preparation and on 
the other hand, charge of encapsulated compounds affects release of different model compounds [156, 
164]. Longer degumming time led to a pronounced burst release of the neutral dextran derivative. The 
positively charged dextran derivative stated an exception since the release was faster compared to the 
other dextran derivatives. These findings are in line with our previous studies [156]. In the previous 
study, positively charged dextran derivative formed polyelectrolyte complexes with silk fibroin. As a 
result, only a part of the dextran was able to interact with silk fibroin, whereas the rest of positively 
charged dextran underwent phase separation, resulting in a burst release. 
In this study, we compared not only differently charged dextran derivatives, but also different molecular 
weights, and additionally, tailored the release by the modification of silk fibroin. Drug release from silk 
fibroin films was found to be mainly driven by diffusion since the degradation rate of silk fibroin is 
negligible in the release medium [194, 195]. With increasing molecular weight, the remaining amount 
of dextran derivative in the silk fibroin film increased due to limited diffusion through the film (Figure 
2A, B, C). Additionally, the charge of the released compound plays a key role and these findings are 
again in line with our previous study [156], where the release of the negatively charged dextran 
derivative was characterized by matrix diffusion and electrostatic repulsion. The release of the positively 
charged dextran derivative stated an exception, since the release was slower compared to the other 
dextran derivatives. By introduction of 0.1 or 1.0 equivalents of crosslinker, MDT could be significantly 
increased. Our hypothesis stats that the crosslinking of SF films takes mainly place on the film surface. 
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With a higher degree of crosslinking, the film becomes denser and therefore, diffusion is more and more 
aggravated. 
To expand this functionalization strategy, the PEG linker can be replaced by a bioresponsive crosslinker, 
e.g. a peptide crosslinker. This peptide crosslinker is then cleaved in presence of e.g. inflammatory 
mediators and the encapsulated drug is release in response, whereas in absence of the trigger no or very 
slow release takes place. This strategy could path a new way for controlled and self-regulating drug 
release.  
5. Conclusion 
Properties of the encapsulated compound (molecular weight, charge) as well as the interaction of the 
latter with the polymer matrix were found to be key factors for drug release from SF matrices. With a 
higher molecular weight, the release of dextran derivative was slower due to the limited diffusion 
through the SF matrix. Crosslinking of the tyrosine residues of SF via click chemistry was found to offer 
an additional option to control drug release. Especially, the mild reaction conditions (aqueous solution, 
room temperature) are an advantage compared to other possible modifications. With the introduction of 
the PEG crosslinker, the properties of silk fibroin could be tailored, a higher hydrophilicity and swelling 
was achieved. Finally, the PEG linker could be exchanged with a bioresponsive linker, resulting in an 
endogenous release of the encapsulated compound. 
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4. Conclusion and Outlook 
The most straightforward way for drug incorporation is the simple mixing of the drug with the matrix 
and then, further processing into the final drug delivery system. Therefore, the integrity of the matrix 
and the preservation of the biological activity has to be ensured. Other possibilities to incorporate the 
drug into the matrix are e.g. by adsorption or covalent binding. Currently, 50 to 60% of the active 
pharmaceutical ingredients available on the market are poorly water-soluble.  Therefore, the formulation 
of these ingredients is one of the major challenges in the pharmaceutical industry. Silk fibroin can 
provide a range of properties to meet these expectations, allowing the encapsulation of differently 
charged and high molecular weight compound and due to its amphiphilic character additionally the 
encapsulation of hydrophobic compounds.  
The aim of this thesis was to establish a silk fibroin based drug delivery system that can be produced 
and loaded under aqueous conditions, while allowing the encapsulation of drugs with different 
properties. Therefore, SF was characterized regarding different degumming time with the standard 
degumming reagent sodium carbonate, other degumming reagents (enzymes, ionic liquids) were 
considered as alternative and the influence of these factors on molecular weight distribution and 
mechanical strength were studied. We found that with longer degumming times, the molecular weight 
distribution became broader. However, SF was still able to form β-sheets to the same extend, suggesting 
that during degradation the hydrophobic blocks of SF remain intact. Anion exchange chromatography 
showed a shift in retention time, stating that the degradation takes mainly place in the hydrophilic 
segments of SF.  
High levels of drug loading (up to 25%) were possible, when using SF films as carrier system. Longer 
degumming times led to a faster burst release of the neutral dextran derivative compared to shorter 
degumming times due to the higher diffusivity through the film. As opposed to this, the negatively 
charged dextran showed an over-all fast release and with longer degumming times a slower release 
because of the decrease of matrix charge. Interestingly, the positively charged dextran stated an 
exception, since it showed an over-all faster release compared to all other dextran derivatives. This is 
due to the fact that only a part of the positively charged dextran can interact with the negatively charged 
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SF, leading to phase separation and as a result, to a burst release. Besides the different charges, different 
molecular weights were studied, ranging from 10 to 70 kDa, whereas a higher molecular weight led to 
a sustained release, showing that the release from SF films is mainly diffusion controlled. These studies 
showed that on the one hand, the purification process is a key factor for the use of SF as drug delivery 
system and on the other hand, the properties of the encapsulated compound. However, to limit the 
diffusion controlled release, SF can be chemically modified, either by covalent binding of the drug to 
the drug delivery system or by crosslinking of the drug delivery system. We were able to successfully 
incorporate a PEG crosslinker to the tyrosine residues of the SF and significantly decrease the release 
rate of the dextran derivatives. The advantage of this crosslinking procedure is the processing under very 
mild conditions (room temperature, aqueous conditions) and furthermore, the surface of the films can 
be tailored according to the application form and target location. 
As mentioned above, silk fibroin and other biomaterials possess the advantage, among others, of good 
biocompatibility, non-toxicity and biodegradability. Thus, they are versatile carriers for drug delivery 
for small molecules, genes and biologicals. With a fully characterized SF starting material, the further 
formulation work can be conducted in a systematic manner, beginning with the appropriate SF matrix, 
the selection of the processing parameters and subsequent with a suitable drug candidate in order to 
achieve targeting and to control the pharmacokinetics. Furthermore, the potential Silk fibroin based drug 
delivery has to show significantly improvement regarding clinical outcome and patient compliance 
compared to already existing drug delivery systems. Where other polymers like PLGA (due to the acidic 
degradation products or the need of organic solvents) failed, there might the opportunity to use SF. 
For each drug candidate, not only its potency, but also the physicochemical properties (hydrophilicity, 
molecular weight and charge) have to be taken into consideration, since the SF-drug interactions 
strongly affect the release mechanism and the pharmacokinetics. In addition, immediate burst release 
might result from insufficient drug encapsulation and/or phase separation due to either supersaturation 
of binding sites or other occurring events during formulation. While these classic drug delivery systems 
control location and time of the released drug, a novel approach for drug delivery will be a bioresponsive, 
on-demand system that can respond to its environment. In our third study, we incorporated a PEG 
crosslinker in the SF films, aiming for more sustained release. In pre-trials, we exchanged the PEG 
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crosslinker for an MMP-sensitive linker. Unfortunately, we could not control the MMP-dependent 
release of the dextran derivatives. MMP-9 has a molecular weight of 92 kDa. When comparing this 
molecular weight to the molecular weight of the encapsulated compound, it can be seen that the release 
of 70 kDa dextran is already very slow. This means that the diffusion through the silk fibroin matrix is 
already limited; conversely, this suggests that the diffusion of the MMP into the SF film is restricted by 
its size. Additionally, to the limited space to diffuse into the film, the enzyme needs to partly unfold to 
bind to its substrate, meaning that even more space is needed.  As a result, only the MMP-sensitive 
crosslinker at the surface are accessible for the enzyme. Therefore, further studies regarding the porosity 
and how to control it should be conducted. Alternatively, the drug could be directly bound to the MMP-
sensitive linker, virtually the drug delivery system would become a prodrug. 
Another promising approach is treatment of chronic wounds (e.g. diabetic ulcer) and tumor tissue, since 
they are characterized by high MMP levels, making them an attractive target. The high MMP level can 
be used to trigger the localized release of e.g. siRNA for specific MMP inhibition. The ability of siRNA 
to inhibit protein expression on a transcriptional level is an attractive option for the treatment of many 
diseases that are characterized by e.g. an overexpression of enzymes. The advantage of this specific and 
localized treatment is the reduced side effects compared to systemically administered formulations. 
In general, this thesis provides a toolbox for a more precise characterization of the starting material silk 
fibroin that can be used as for initial quality assessment as well as for in-process controls, and in addition, 
provides an insight into the future possibilities for bioresponsive drug delivery. 
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